(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/045920 A1

(51) International Patent Classification[7]: C07D 213/42

(21) International Application Number: PCT/US02/37510

(22) International Filing Date:
22 November 2002 (22.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/333,464 27 November 2001 (27.11.2001) US

(71) Applicant *(for all designated States except US)*: **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DEVITA, Robert, J.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **CHANG, Lehua** [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **HOANG, MyLe Thi** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **JIANG, Jinlong** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **LIN, Peter** [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **SAILER, Andreas, W.** [DE/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-AMINOQUINOLINE COMPOUNDS



(I)

(57) Abstract: The present invention is concerned with compounds of the general Formula I : and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington s disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

WO 03/045920 A1

TITLE OF THE INVENTION
4-AMINOQUINOLINE COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATIONS

Not applicable.

BACKGROUND OF THE INVENTION

Obesity, defined as excess adiposity for a given body size, results from a chronic imbalance between energy intake and energy expenditure. Body mass index (BMI, kg/m^2) is an accepted clinical estimate of being overweight (BMI 25 to 30) and of obesity (BMI > 30). A BMI above 30 kg/m^2 significantly increases the risk of diabetes, hypertension, dyslipidemias and cardiovascular disease, gallstones, osteoarthritis and certain forms of cancer and reduces life expectancy.

In the vast majority of obese individuals, the cause of the excess adiposity is not immediately apparent. A currently accepted working hypothesis is that obesity is the result of a maladaptation of the innate metabolic response to environmental challenges such as unlimited availability of low cost/ energy dense foods and sedentariness (Hill et al., Science 1998; 280:1371). The study of energy intake in free living humans has met with only limited success and definitive experimental evidence that hyperphagia causes most forms of human obesity is lacking. Following the discovery of leptin, the interest in the neurohormonal regulation of food intake has regained momentum. However, while much knowledge has been gained on the regulation of food intake in rodents and other animal species, the understanding of the neurophysiology of feeding behavior in humans remains extremely limited.

Neuropeptides present in the hypothalamus play a major role in mediating the control of body weight. (Flier, *et al.*, 1998. *Cell, 92*, 437-440.) Melanin-concentrating hormone (MCH) is a cyclic 19-amino acid neuropeptide synthesized as part of a larger pre-prohormone precursor in the hypothalamus which also encodes neuropeptides NEI and NGE. (Nahon, *et al.*, 1990. *Mol. Endocrinol. 4*, 632-637.) MCH was first identified in salmon pituitary, and in fish MCH affects melanin aggregation thus affecting skin pigmentation. In trout and in eels MCH has also been shown to be involved in stress induced or CRF–stimulated ACTH release. (Kawauchi, *et al.*, 1983. *Nature 305*, 321-323.)

In humans two genes encoding MCH have been identified that are expressed in the brain. (Breton, *et al.*, 1993. *Mol. Brain Res. 18*, 297-310.) In mammals MCH has been localized primarily to neuronal cell bodies of the hypothalamus which are implicated in the control of food intake, including perikarya of the lateral hypothalamus and zona inertia. (Knigge, *et al.*, 1996. *Peptides 17*, 1063-1073.)

Pharmacological and genetic evidence suggest that the primary mode of MCH action is to promote feeding (orexigenic). MCH mRNA is up-regulated in fasted mice and rats, in the *ob/ob* mouse and in mice with targeted disruption in the gene for neuropeptide Y (NPY). (Qu, *et al.*, 1996. *Nature 380, 243-247*, and Erickson, *et al.*, 1996. *Nature 381*, 415-418.) Injection of MCH centrally intracelebroventricular (ICV) stimulates food intake and MCH antagonizes the hypophagic effects seen with α melanocyte stimulating hormone (αMSH). (Qu, *et al.*, 1996. *Nature 380, 243-247.*) MCH deficient mice are lean, hypophagic and have increased metabolic rate. (Shimada, *et al.*, 1998. *Nature 396*, 670-673.)

MCH action is not limited to modulation of food intake as effects on the hypothalamic-pituitary-axis have been reported. (Nahon, 1994. *Critical Rev. in Neurobiol. 8*, 221-262.) MCH may be involved in the body response to stress as MCH can modulate the stress-induced release of CRF from the hypothalamus and ACTH from the pituitary.

In addition, MCH neuronal systems may be involved in reproductive or maternal function. MCH transcripts and MCH peptide were found within germ cells in testes of adult rats, suggesting that MCH may participate in stem cell renewal and/or differentiation of early spermatocytes (Hervieu et al., 1996). MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual activity in female rats (Gonzalez et al., 1996). In ovariectomized rats primed with estradiol, MCH stimulated luteinizing hormone (LH) release while anti-MCH antiserum inhibited LH release (Gonzalez et al., 1997). The zona incerta, which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the pre-ovulatory LH surge (MacKenzie et al., 1984). Therefore modulators of MCH receptors may be useful in the prevention and treatment of reproductive function. MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin. Therefore, modulators of MCH receptors may be useful in the prevention and treatment of obesity, Cushing's disease, sexual function, appetite and eating disorders, obesity, diabetes, cardiovascular

disease, hypertension, dyslipidemia, myocardial infarction, gall stones, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in the elderly), binge eating disorders including bulimia, anorexia, kidney function, diuresis, reproductive function and sexual function.

Two receptor subtypes have been identified in humans, MCH-1R and MCH-2R. Both receptors, as well as the gene for the MCH peptide, have been mapped to regions previously reported to contain a susceptibility gene for psychiatric disorders. In particular, MCH-1R was mapped to chromosome 22q13.2 (Kolakowski et al. 1996). The possibility of linkage for schizophrenia susceptibility locus in this area was suggested by independent studies from 2 groups (Pulver et al. 1994, Coon et al. 1994). In addition, a more recent study (Stoeber et al. 2000) of samples from patients with periodic catatonia, a clinical subtype of unsystematic schizophrenia suggested possible linkage of the region around 22q13. Human genetics implicates these loci not only for schizophrenia but also for bipolar disorder. The second MCH receptor (MCH-2R) has been mapped to chromosome 6q16.2-16.3 (Sailer et al., 2001). Cao et al. (1997) were the first to report evidence of a schizophrenia susceptibility locus in that area. This initial report was confirmed and extended by other reports (Martinez et al. 1999, Kaufmann et al. 1998, Levinson et al. 2000). Schizophrenia has been recognized as a disorder with profound deficits in information-processing and attentional abnormalities. One of the few possible paradigms available to assess these types of deficits in information processing is sensory gating, a filtering process which can be demonstrated by using a paired auditory stimulus. Miller et al. (1993) examined the effects of ICV administered MCH on the decrease in amplitude of the second of two tone-evoked CNS potentials that can be measured when pairs of identical tones are presented 500 ms apart. They found that MCH application decreased sensory gating in this paradigm. Based on pathogenesis and pathophysiology (reviewed in Lewis and Liebermann (2000)) several brain areas have been implicated in schizophrenia; all of which show high expression for MCH receptors: thalamus, midbrain, nucleus accumbens, temporo-limbic, and prefrontal cortices. These studies and findings support the use of MCH receptor modulators in the treatment and prevention of schizophrenia.

Kelsoe et al. (2001) recently reported on a genome survey indicating a possible susceptibility locus for bipolar disorder identified on 22q (Kelsoe et al. 2001). The MCH gene which encodes the MCH pro-peptide was mapped to chromosome 12q23.1. This area has been identified by Morissette et al. (1999) in a

genome wide scan for susceptibility loci for bipolar disorder in families in the Province of Quebec. In addition, Ewald et al. (1998) showed significant linkage to chromosome 12q23.1 (maximum lod score 3.37) in Danish families suffering from bipolar affective disorder. In addition, Presse et al. (1997) have shown that lithium, the "gold standard" and most appropriate initial treatment for the depressive phase of bipolar disorder, can alter MCH mRNA levels in NGF-treated PC12 cells by increasing mRNA stability. These studies and findings support the use of MCH receptor modulators in the treatment and prevention of bipolar disorder and depression.

Philippe and colleagues (1999) performed a genome-wide screen for a autism susceptibility gene and found suggestive linkage for the region of chromosome 6q16.2-16.3 (maximum lod score 2.23). This finding supports the use of MCH receptor modulators in the treatment of autism.

In all species studied to date, a major portion of the neurons of the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers (Bittencourt et al., 1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Thus, modulators of MCH receptor function may be useful in the treatment and prevention of movement disorders, such as Parkinson's disease, Parkinson-like syndromes and Huntingdon's Chorea in which extrapyramidal circuits are known to be involved.

Human genetic linkage studies have located authentic hMCH loci on chromosome 12 (12q23-24) and the variant hMCH loci on chromosome 5 (5q12- 13) (Pedeutour et al., 1994). Locus 12q23-24 coincides with a locus to which autosomal dominant cerebellar ataxia type II (SCA2) has been mapped (Auburger et al., 1992; Twells et al., 1992). This disease comprises neurodegenerative disorders, including an olivopontocerebellar atrophy. Furthermore, the gene for Darier's disease, has been mapped to locus 12q23-24 (Craddock et al., 1993). Dariers' disease is characterized by abnormalities in keratinocyte adhesion and mental illnesses in some families. In view of the functional and neuroanatomical patterns of the MCH neural system in the rat and human brains, the MCH gene may represent a good candidate for SCA2 or

Darier's disease. Therefore, modulators of MCH receptors may be useful in the treatment of mental disorders including manic depression, depression, schizophrenia, mood disorders, delirium, dementia, severe mental retardation, anxiety, stress, cognitive disorders, and dyskinesias including Parkinson's disease, Tourette's syndrome, Huntington's disease, cerebellar ataxia, seizures, locomotor disorders, attention deficit disorder (ADD) and substance abuse disorders.

Further, the gene responsible for chronic or acute forms of spinal muscular atrophies has been assigned to chromosome 5q12-13 using genetic linkage analysis (Melki et al., 1990; Westbrook et al., 1992). Therefore, modulators of MCH receptors may be useful in treating muscular dystrophy and dyskinesias, including Parkinson's disease, Tourette's syndrome, Huntington's disease, cerebellar ataxia, and seizures.

Still further, modulators of MCH receptor binding may also be useful in treating epilepsy. In the PTZ seizure model, injection of MCH prior to seizure induction prevented seizure activity in both rats and guinea pigs, suggesting that MCH-containing neurons may participate in the neural circuitry underlying PTZ-induced seizure (Knigge and Wagner, 1997).

MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats (McBride et al., 1994), raising the possibility that MCH receptor antagonists may be beneficial for memory storage and/or retention.

A role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. MCH receptor modulators may be useful as antinociceptives or as analgesics, particularly for the treatment of neuropathic pain.

Finally, MCH may participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume (Parkes, 1996). Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, the results indicate that MCH may be an important peptide involved in the central control of fluid homeostasis in mammals. Therefore, modulators of MCH receptors may be useful in kidney function and diuresis.

PCT publication WO 01/21169 to Takeda discloses MCH antagonists of the structural formula shown below:



;

and PCT publication WO 01/21577 discloses MCH antagonists of the structural formula below:



.

Lanza et al., J.Med.Chem. 1992, 35:252-258, describe substituted 4,6-diaminoquinolines useful as inhibitors of C5a receptor binding. Shinkai, et al., J. Med Chem. 2000, 43:4667-4677, describe 4-aminoquinolines as nociceptin antagonists with analgesic activity.

PCT publication WO 96/28446 discloses N-cycloalkylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines as inhibitors of cGMP phosphodiesterase and US 5,942,520 claims treating precancerous lesions in mammals with compounds of the structural formula shown below:



.

US 4,701,459 and EP 0 252 503 disclose 2,3-dihydro-2-oxo-1H-imidazo[4,5-b]quinolinyl amine derivatives of structural formula:



as useful in inhibiting blood platelet aggregation. US 4,013,665 claims antiviral, substituted 1,3-dimethyl-1H-pyrazolo[3,4b]quinolines of structural formula below:



PCT publication WO 99/48492 discloses nociceptin antagonists of the formula below:



PCT publication WO 99/53924 discloses analgesic agent of the formula below:



;

and PCT publication WO 99/19326 discloses compounds of the formula below:



The compounds of the present invention are modulators of the MCH-1R receptor and are useful in the treatment, prevention and suppression of diseases mediated by the MCH-1R receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the MCH-1R receptor. As such, compounds of the present invention are useful for the treatment or prevention of obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, gall stones, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), binge eating disorders including bulimina, anorexia, mental disorders including manic depression, depression, schizophrenia, mood disorders, delirium, dementia, severe mental retardation, anxiety, stress, cognitive disorders, sexual function, reproductive function, kidney function, diuresis, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias including Parkinson's disease, Parkinson-like syndromes, Tourette's syndrome, Huntington's disease, epilepsy, improving memory function, and spinal muscular atrophy.

SUMMARY OF THE INVENTION

The present invention is concerned with compounds of the general Formula I:



(I)

and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone (MCH) receptor antagonists.

As melanin concentrating hormone receptor antagonists, the compounds of the present invention are useful in the treatment, prevention and suppression of diseases mediated by the MCH receptor. In particular, compounds of the present invention are selective antagonists of the MCH-1R subtype receptor. As MCH-1R antagonists, the compounds of the present invention may be useful in treating the following conditions: obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, gall stones,

osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), binge eating disorders including bulimina, anorexia, mental disorders including manic depression, depression, schizophrenia, mood disorders, delirium, dementia, severe mental retardation, anxiety, stress, cognitive disorders, sexual function, reproductive function, kidney function, diuresis, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias including Parkinson's disease, Parkinson-like syndromes, Tourette's syndrome, Huntington's disease, epilepsy, improving memory function, and spinal muscular atrophy.

The present invention is also concerned with treatment of these conditions, and the use of compounds of the present invention for manufacture of a medicament useful in treating these conditions.

The invention is also concerned with pharmaceutical formulations comprising one of the compounds as an active ingredient.

The invention is further concerned with processes for preparing the compounds of this invention.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention are represented by the compound of structural formula I:



(I)

and pharmaceutically acceptable salts thereof.

In one embodiment of the present invention, R^1 is selected from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) C_{2-6} alkenyl,
(4) C_{2-6} alkynyl,
(5) cycloalkyl-C_{0-6} alkyl,
(6) heterocycloalkyl-C_{0-10} alkyl,
(7) aryl-C_{0-10} alkyl, and

(8) heteroaryl-C_{0-10} alkyl;

wherein alkyl, alkenyl, and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom.

In one class of this embodiment of the present invention, R^1 is selected from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) C_{2-6} alkenyl,
(4) cycloalkyl-C_{0-6} alkyl,
(5) heterocycloalkyl-C_{0-6} alkyl,
(6) aryl-C_{0-6} alkyl, and
(7) heteroaryl-C_{0-10} alkyl;

wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b.

In one subclass of this class of the invention, R^1 is hydrogen, or C_{1-6} alkyl, optionally substituted with one to three substituents independently selected from R^a.

In another subclass of this class of the invention, R^1 is selected from :

(1) hydrogen,
(2) methyl,
(3) ethyl, and
(4) propyl,

optionally substituted with one to three substituents independently selected from R^a.

In one embodiment of the present invention, R^2 is selected from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) C_{2-6} alkenyl,
(4) C_{2-6} alkynyl,
(5) cycloalkyl-C_{0-6} alkyl,
(6) heterocycloalkyl-C_{0-10} alkyl,
(7) aryl-C_{0-10} alkyl, and

(8) heteroaryl-C_{0-10} alkyl;

wherein alkyl, alkenyl, and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom.

In one class of this embodiment of the present invention, R^2 is selected from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(1) C_{2-6} alkenyl,
(2) cycloalkyl-C_{0-6} alkyl,
(3) heterocycloalkyl-C_{0-6} alkyl,
(4) aryl-C_{0-6} alkyl, and
(5) heteroaryl-C_{0-10} alkyl;

wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b.

In one subclass of this class, R^2 is selected from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) cycloalkyl-C_{0-6} alkyl,
(4) heterocycloalkyl-C_{0-6} alkyl,
(5) aryl-C_{0-6} alkyl, and
(6) heteroaryl-C_{0-10} alkyl;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b.

In another subclass of this class of the invention, R^2 is selected from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) cycloalkyl-C_{0-6} alkyl,
(4) heterocycloalkyl-C_{0-6} alkyl, and

(5) aryl-C_{0-6} alkyl,

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b.

In yet another subclass of this class of the invention, R^2 is selected from the group consisting of:

(1) hydrogen,
(2) methyl,
(3) ethyl,
(4) n-propyl,
(5) isopropyl,
(6) t-butyl,
(7) n-butyl,
(8) cyclopropyl,
(9) cyclobutyl,
(10) cyclopentyl,
(11) cyclohexyl,
(12) heterocycloalkyl-C_{0-6} alkyl, wherein the heterocycloalkyl moiety is selected from azetidinyl, pyrrolidinyl, and pyridyl, and
(13) phenyl-C_{0-3}alkyl,

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b.

In another embodiment of the present invention, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, optionally containing one or two additional heteroatoms selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom. In one class of this embodiment of the invention, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered

bridged or unbridged heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with an R^b substituent. In one subclass of this class, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, either unsubstituted or substituted with an R^b substituent. In yet another subclass of the present invention, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, selected from: azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, 1-thia-4-azacyclohexyl, azacycloheptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl, and 3-azabicyclo[3.2.2]nonyl, either unsubstituted or substituted with an R^b substituent. In still another subclass of the present invention, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 6-membered unbridged heterocyclic ring, selected from: azetidinyl, pyrrolidinyl, piperidinyl, either unsubstituted or substituted with an R^b substituent.

In yet another embodiment of this invention, R^1 and R^2 together with the nitrogen atom to which they are attached, are selected from: unsubstituted amino, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino, N-cyclopropylamino, N-cyclobutylamino, azetidinyl, pyrrolidinyl, piperidinyl, and 4-(4-fluorophenyl)piperidinyl.

In yet another embodiment of the present invention, R^3 is selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) C_{1-8}alkyl,
(4) perfluoro C_{1-6} alkyl,
(5) C_{2-6} alkenyl,
(6) C_{2-6} alkynyl,
(7) cycloalkyl,
(8) cycloalkyl-C_{1-6} alkyl,
(9) cycloheteroalkyl,
(10) cycloheteroalkyl-C_{1-6} alkyl,

(11) aryl,
(12) aryl-C_{1-6} alkyl,
(13) heteroaryl,
(14) heteroaryl-C_{1-6} alkyl,
(15) $-OR^7$,
(16) $-NR^7R^7$,
(17) $-CO_2R^7$,
(18) cyano, and
(19) $-C(O)NR^7R^7$;

wherein alkyl, alkenyl and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom.

In one class of this embodiment of the present invention, R^3 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) C_{2-6} alkenyl,
(6) cycloalkyl,
(7) cycloalkyl-C_{1-6} alkyl,
(8) cycloheteroalkyl,
(9) cycloheteroalkyl-C_{1-6} alkyl,
(10) aryl,
(11) aryl-C_{1-6} alkyl,
(12) heteroaryl,
(13) heteroaryl-C_{1-6} alkyl,
(14) $-OR^7$,
(15) $-NR^7R^7$,
(16) $-CO_2R^7$, and
(17) $-C(O)NR^7R^7$;

wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent.

In one subclass of this class, R^3 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) –OH,
(6) $-OCH_3$,
(7) $-NH_2$,
(8) $-CO_2R^7$, and
(9) $-C(O)NH_2$;

wherein alkyl moieties above are optionally substituted with one to two substituents independently selected from R^a.

In another subclass of this class, R^3 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) –OH,
(6) $-OCH_3$,
(7) $-NH_2$,
(8) $-CO_2H$,
(9) $-CO_2CH_3$,
(10) $-CO_2CH_2CH_3$, and
(11) $-C(O)NH_2$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a.

In yet another subclass of this class, R^3 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,

(5) –OH,
(6) –OCH_3,
(7) –NH_2,
(8) -CO_2H,
(9) –CO_2CH_3, and
(10) –$CO_2CH_2CH_3$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a.

In still another subclass of this class, R^3 is selected from hydrogen and –$CO_2CH_2CH_3$. In yet another subclass, R^3 is hydrogen.

In still another embodiment of the present invention, R^4 is selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) perfluoro C_{1-6} alkyl,
(5) C_{2-6} alkenyl,
(6) C_{2-6} alkynyl,
(7) cycloalkyl,
(8) cycloalkyl-C_{1-6} alkyl,
(9) cycloheteroalkyl,
(10) cycloheteroalkyl-C_{1-6} alkyl,
(11) aryl,
(12) aryl-C_{1-6} alkyl,
(13) heteroaryl,
(14) heteroaryl-C_{1-6} alkyl,
(15) –OR^7,
(16) –NR^7R^7,
(17) -CO_2R^7, and
(18) –$C(O)NR^7R^7$;

wherein alkyl, alkenyl and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to four

substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom.

In one class of this embodiment of the present invention, R^4 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) C_{2-6} alkenyl,
(6) cycloalkyl,
(7) cycloalkyl-C_{1-6} alkyl,
(8) cycloheteroalkyl,
(9) cycloheteroalkyl-C_{1-6} alkyl,
(10) aryl,
(11) aryl-C_{1-6} alkyl,
(12) heteroaryl,
(13) heteroaryl-C_{1-6} alkyl,
(14) $-OR^7$,
(15) $-NR^7R^7$,
(16) $-CO_2R^7$, and
(17) $-C(O)NR^7R^7$;

wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent.

In one subclass of this class of the invention, R^4 is selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) cycloalkyl,
(6) cycloheteroalkyl,
(7) aryl,
(8) aryl-C_{1-6} alkyl,
(9) heteroaryl,

(10) –OH,

(11) –OCH,

(12) $-NH_2$,

(13) $-CO_2R^7$, and

(14) $-C(O)NH_2$;

wherein alkyl moieties above are optionally substituted with one to four substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent.

In another subclass of this class of the invention, R^4 is selected from:

(1) C_{1-8} alkyl,

(2) trifluoromethyl,

(3) cycloalkyl,

(4) cycloheteroalkyl,

(5) aryl,

(6) heteroaryl,

(7) $-NH_2$,

(8) $-CO_2H$,

(9) $-CO_2CH_3$, and

(10) $-CO_2CH_2CH_3$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent.

In yet another subclass of this class, R^4 is selected from:

(1) C_{1-8} alkyl,

(2) trifluoromethyl,

(3) cyclobutyl,

(4) cyclopentyl,

(5) cyclohexyl,

(6) phenyl,

(7) $-CO_2H$,

(8) CO_2CH_3, and

(9) $-CO_2CH_2CH_3$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a, and cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent.

In still another subclass of this class, R^4 is selected from: methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, 2,2-dimethylpropyl, 1-methylpropyl, n-pentyl, n-hexyl, phenyl, methoxymethyl, methylthiomethyl, cyclobutyl, cyclopentyl, and cyclohexyl.

In one embodiment of the present invention, R^3 and R^4 are not both hydrogen.

In another embodiment of the present invention, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered heterocycloalkyl or cycloalkyl ring, either unsubstituted or substituted with one to four substituents independently selected from R^b. In one class of this embodiment of the present invention, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered heterocycloalkyl or cycloalkyl ring, either unsubstituted or substituted with an R^b substituent. In one subclass of this embodiment, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered cycloalkyl ring, either unsubstituted or substituted with oxo or hydroxy. In another subclass of this class, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a cyclohexyl ring, either unsubstituted or substituted with oxo or hydroxy.

In one embodiment of the present invention, R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-6} alkyl,
(4) perfluoro C_{1-6} alkyl,
(5) $-OR^7$, and
(6) $-NR^7R^7$.

In one class of this embodiment of the present invention, R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) methyl,
(4) trifluoromethyl,
(5) hydroxy,

(6) methoxy,
(7) phenoxy,
(8) $-NH_2$,
(9) $-NH(CH_3)$, and
(10) $-N(CH_3)_2$.

In one class of this embodiment of the invention, R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) methyl,
(4) trifluoromethyl,
(5) hydroxy,
(6) methoxy,
(7) phenoxy,
(8) $-NH_2$,
(9) $-NH(CH_3)$, and
(10) $-N(CH_3)_2$.

In one subclass of this invention, R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) methyl,
(4) trifluoromethyl,
(5) hydroxy, and
(6) methoxy.

In another subclass of this invention, R^5 is hydrogen.

In another embodiment of the present invention, R^6 is selected from:

(1) $-(CH_2)_n-R^7$,
(2) $-(CH_2)_n$-aryl-R^7,
(3) $-(CH_2)_n$-heteroaryl-R^7,
(4) $-(CH_2)_n$-heterocycloalkyl-R^7,
(5) $-(CH_2)_nC{\equiv}N$,
(6) $-(CH_2)_nCON(R^7)_2$,
(7) $-(CH_2)_nCO_2R^7$,
(8) $-(CH_2)_nCOR^7$,
(9) $-(CH_2)_nNR^7C(O)R^7$,
(10) $-(CH_2)_nNR^7C(O)(CH_2)_nSR^7$

(11) $-(CH_2)_nNR^7CO_2R^7$,
(12) $-(CH_2)_nNR^7C(O)N(R^7)_2$,
(13) $-(CH_2)_nNR^7SO_2R^7$,
(14) $-(CH_2)_nS(O)_pR^7$,
(15) $-(CH_2)_nSO_2N(R^7)_2$,
(16) $-(CH_2)_nOR^7$,
(17) $-(CH_2)_nOC(O)R^7$,
(18) $-(CH_2)_nOC(O)OR^7$,
(19) $-(CH_2)_nOC(O)N(R^7)_2$,
(20) $-(CH_2)_nN(R^7)_2$, and
(21) $-(CH_2)_nNR^7SO_2N(R^7)_2$,
wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a.

In one class of this invention, R^6 is selected from:

(1) $-(CH_2)_n-R^7$,
(2) $-(CH_2)_n$-aryl-R^7,
(3) $-(CH_2)_n$-heteroaryl-R^7,
(4) $-(CH_2)_n$-heterocycloalkyl-R^7,
(5) $-(CH_2)_nC{\equiv}N$,
(6) $-(CH_2)_nCON(R^7)_2$,
(7) $-(CH_2)_nCO_2R^7$, provided that n is 1, 2, 3, 4, or 5,
(8) $-(CH_2)_nCOR^7$,
(9) $-(CH_2)_nNR^7C(O)R^7$, provided that n is 1, 2, 3, 4, or 5,
(10) $-(CH_2)_nNR^7C(O)(CH_2)_nSR^7$
(11) $-(CH_2)_nNR^7CO_2R^7$,
(12) $-(CH_2)_nNR^7C(O)N(R^7)_2$,
(13) $-(CH_2)_nNR^7SO_2R^7$, provided that n is 1, 2, 3, 4, or 5,
(14) $-(CH_2)_nS(O)_pR^7$,
(15) $-(CH_2)_nSO_2N(R^7)_2$,
(16) $-(CH_2)_nOR^7$,
(17) $-(CH_2)_nOC(O)R^7$,
(18) $-(CH_2)_nOC(O)OR^7$,
(19) $-(CH_2)_nOC(O)N(R^7)_2$,
(20) $-(CH_2)_nN(R^7)_2$, provided that when n is zero, at least one R^7 is other than hydrogen, phenyl and alkyl, and

(21) -$(CH_2)_nNR^7SO_2N(R^7)_2$,

wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a.

In one class of the present invention, R^6 is selected from:

(1) –$(CH_2)_n$-R^7,
(2) -$(CH_2)_n$-aryl-R^7,
(3) -$(CH_2)_n$-heteroaryl-R^7,
(4) -$(CH_2)_n$-heterocycloalkyl-R^7,
(5) -$(CH_2)_nCON(R^7)_2$,
(6) -$(CH_2)_nNR^7C(O)R^7$,
(7) -$(CH_2)_nNR^7C(O)(CH_2)_nSR^7$
(8) -$(CH_2)_nNR^7C(O)N(R^7)_2$,
(9) -$(CH_2)_nNHSO_2R^7$,
(10) -$(CH_2)_nN(R^7)_2$, and
(11) -$(CH_2)_nNR^7SO_2N(R^7)_2$,

wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a.

In another class of the present invention, R^6 is selected from:

(1) -R^7,
(2) –heteroaryl-R^7,
(3) -$CONHR^7$,
(4) -$CON(R^7)(CH_3)$,
(5) -CH_2CONHR^7,
(6) -$CH_2CON(R^7)(CH_3)$,
(7) -$CH_2NHC(O)R^7$,
(8) -$NHC(O)R^7$,
(9) -$(CH_2)_nNHC(O)(CH_2)_nSR^7$
(10) -$(CH_2)_nNHC(O)N(CH_3)(R^7)$,
(11) -$(CH_2)_nNHC(O)NH(R^7)$,
(12) -$(CH_2)_nNHSO_2R^7$,
(13) -$NH(R^7)$,
(14) –$N(COCH_3)(R^7)$,
(15) -$(CH_2)_nNH(R^7)$, and
(16) -$(CH_2)_nN(COCH_3)(R^7)$,

wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a.

In a particular subclass of the present invention, R^6 is –oxadiazolyl-R^7.

In yet another embodiment of the present invention, R^7 is independently selected at each occurrence from the group consisting of:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C_{1-3} alkyl,
(8) heteroaryl C_{1-3} alkyl,
(9) cycloalkyl C_{1-3} alkyl,
(10) heterocycloalkyl C_{1-3} alkyl,
(11) aryl C_{2-3} alkenyl,
(12) heteroaryl C_{2-3} alkenyl,
(13) cycloalkyl C_{2-3} alkenyl, and
(14) heterocycloalkyl C_{2-3} alkenyl,

wherein the alkyl and alkenyl moieties are optionally substituted with one to four substituents selected from R^a, and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to four substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom. In one class of the compounds of the present invention, in R^7, the alkyl and alkenyl moieties are optionally substituted with one to three substituents selected from R^a, and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom.

In one class of the present invention, R^7 is independently selected at each occurrence from:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) aryl, selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl,

benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,

(4) heteroaryl, selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,

(5) cycloalkyl, selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo [2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl,

(6) heterocycloalkyl, selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octane, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl, indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl,

(7) aryl C_{1-3} alkyl, wherein the aryl moiety is selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,

(8) heteroaryl C_{1-3} alkyl, wherein the heteroaryl moiety is selected: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl,

thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,

(9) cycloalkyl C_{1-3} alkyl, wherein the cycloalkyl moiety is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo[2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl,

(10) heterocycloalkyl C_{1-3} alkyl, wherein the heterocycloalkyl moiety is selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl,indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl,

(11) aryl C_{2-3} alkenyl, wherein the aryl moiety is selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,

(12) heteroaryl C_{2-3} alkenyl, wherein the heteroaryl moiety is selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl,

triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,

(13) cycloalkyl C_{2-3} alkenyl, wherein the cycloalkyl moiety is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo [2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl, and

(14) heterocycloalkyl C_{2-3} alkenyl, wherein the heterocycloalkyl moiety is selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl,indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl;

wherein the alkyl moieties are optionally substituted with one to three substituents selected from R^a, and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

In another embodiment of the present invention, R^a is independently selected from:

(1) $-OR^d$,
(2) $-NR^dS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^d$,
(6) $-SR^d$,
(7) $-S(O)_2OR^d$,
(8) $-S(O)_pN(R^d)_2$,
(9) $-N(R^d)_2$,
(10) $-O(CR^dR^d)_nN(R^d)_2$,
(11) $-C(O)R^d$,
(12) $-CO_2R^d$,

(13) $-CO_2(CR^dR^d)_nCON(R^d)_2$,
(14) $-OC(O)R^d$,
(15) -CN,
(16) $-C(O)N(R^d)_2$,
(17) $-NR^dC(O)R^d$,
(18) $-OC(O)N(R^d)_2$,
(19) $-NR^dC(O)OR^d$,
(20) $-NR^dC(O)N(R^d)_2$,
(21) $-CR^d(N\text{-}OR^d)$,
(22) $-CF_3$,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;

at each occurrence.

In one class of this embodiment of the present invention, R^a is independently selected from:

(1) $-OR^d$,
(2) $-NHSO_2CH_3$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mCH_3$,
(6) $-SR^d$,
(7) $-S(O)_2OR^d$,
(8) $-S(O)_pN(R^d)_2$,
(9) $-N(R^d)_2$,
(10) $-O(CR^dR^d)_nN(R^d)_2$,
(11) $-C(O)R^d$,
(12) $-CO_2R^d$,
(13) $-CO_2(CR^dR^d)_nCON(R^d)_2$,
(14) $-OC(O)R^d$,
(15) -CN,
(16) $-C(O)N(R^d)_2$,
(17) $-NR^dC(O)R^d$,
(18) $-OC(O)N(R^d)_2$,

(19) -$NR^dC(O)OR^d$,
(20) -$NR^dC(O)N(R^d)_2$,
(21) -$CR^d(N\text{-}OR^d)$,
(22) -CF_3,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;

at each occurrence.

In a subclass of this class of the invention, R^a is independently selected from:

(1) –OR^d,
(2) –$NHSO_2CH_3$,
(3) -NO_2,
(4) halogen,
(5) -$S(O)_mCH_3$,
(6) –SCH_3,
(7) -SCF_3,
(8) -$S(O)_2OH$,
(9) -$S(O)_pN(R^d)_2$,
(10) -$N(CH_3)_2$,
(11) -NH_2,
(12) -$O(CR^dR^d)_nN(R^d)_2$,
(13) -$C(O)R^d$,
(14) -CO_2H,
(15) -CO_2CH_3,
(16) t-butyloxycarbonyl,
(17) -$CO_2(CR^dR^d)_nCON(R^d)_2$,
(18) -$OC(O)R^d$,
(19) -CN,
(20) -$C(O)N(R^d)_2$,
(21) -$NR^dC(O)R^d$,
(22) -$OC(O)N(R^d)_2$,
(23) -$NR^dC(O)OR^d$,
(24) -$NR^dC(O)N(R^d)_2$,

(25) -$CR^d(N\text{-}OR^d)$,

(26) -CF_3,

(27) cycloalkyl,

(28) cycloheteroalkyl, and

(29) oxo;

at each occurrence.

In another embodiment of the present invention, each R^b is independently selected from:

(1) R^a,

(2) -$Sn(CH_3)_3$,

(3) $C_{1\text{-}10}$ alkyl,

(4) $C_{2\text{-}10}$ alkenyl,

(5) $C_{2\text{-}10}$ alkynyl,

(6) heteroaryl,

(7) aryl, and

(8) aryl-$C_{1\text{-}10}$ alkyl;

wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl are optionally substituted with one to four substituents selected from a group independently selected from R^c.

In one class of this embodiment of the present invention, each R^b is independently selected from:

(1) R^a,

(2) -$Sn(CH_3)_3$,

(3) $C_{1\text{-}10}$ alkyl,

(4) $C_{2\text{-}10}$ alkenyl,

(5) heteroaryl,

(6) aryl, and

(7) aryl-$C_{1\text{-}10}$ alkyl;

wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl are optionally substituted with one to four substituents selected from a group independently selected from R^c.

In one subclass of this class of the invention, each R^b is independently selected from:

(1) R^a,

(2) -Sn(CH_3)$_3$,
(3) C_{1-6} alkyl,
(4) C_{2-6} alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-C_{1-10} alkyl;

wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R^a and R^b are optionally substituted with one to four substituents selected from a group independently selected from R^c.

In another subclass of the present invention, each R^b is independently selected from:

(1) -R^a,
(2) -Sn(CH_3)$_3$,
(3) C_{1-6} alkyl,
(4) C_{2-6} alkenyl,
(5) heteroaryl,
(6) phenyl, and
(7) phenyl-C_{1-10} alkyl;

wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R^a and R^b are optionally substituted with one to four substituents selected from a group independently selected from R^c.

In yet another embodiment of the present invention, each R^c is independently selected from:

(1) halogen,
(2) amino,
(3) carboxy,
(4) C_{1-4} alkyl,
(5) C_{1-4} alkoxy,
(6) aryl,
(7) aryl C_{1-4} alkyl,
(8) hydroxy,
(9) -CF_3,
(10) -OC(O)C_{1-4} alkyl,
(11) -OC(O)N(R^d)$_2$, and

(12) aryloxy.

In still another embodiment of the present invention, R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl; C_{2-6} alkynyl; cycloalkyl; cycloalkyl-C_{1-6} alkyl; cycloheteroalkyl; cycloheteroalkyl-C_{1-6} alkyl; aryl; heteroaryl; aryl-C_{1-6} alkyl; and heteroaryl-C_{1-6} alkyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to four substituents independently selected from R^e. In one class of this embodiment of the present invention, the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to two substituents independently selected from a R^e.

In another embodiment of the present invention, each R^e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy.

In still another embodiment of the present invention, each m is independently selected from 1 and 2. In one class of this embodiment, m is 1. In another class of this embodiment m is 2.

In yet another embodiment of the present invention, n is independently elected from 0, 1, 2, 3, 4, and 5 at each occurrence. In one class of this embodiment, each n is independently selected from 0, 1, 2, 3, and 4. In one subclass of this class, n is selected from 0, 1, 2, and 3. In another subclass of this class, n is selected from 0, 1, and 2. In still another subclass of this class, n is 0.

In still another embodiment of the present invention, each p is independently selected from 0, 1, and 2. In one class of this embodiment, p is 0. In another class of this embodiment, p is 1. In still another class of this embodiment, p is 2.

"Alkyl", as well as other groups having the prefix "alk", such as alkoxy, alkanoyl, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethyl butyl, n-heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1-ethylpentyl, 2-ethylpentyl, 3-ethylpentyl, 4-ethylpentyl, 1-propylbutyl,

2-propylbutyl, 3-propylbutyl, 1,1-dimethylpentyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,4-dimethylpentyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl. 2,4-dimethylpentyl, 3,3-dimethylpentyl, 3,4-dimethylpentyl, 4,4-dimethylpentyl, 1-methyl-1-ethylbutyl, 1-methyl-2-ethylbutyl, 2-methyl-2-ethylbutyl, 1-ethyl-2-methylbutyl, 1-ethyl-3-methylbutyl, 1,1-diethylpropyl, n-octyl, n-nonyl, and the like.

"Alkenyl" means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

"Alkynyl" means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched or combinations thereof. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.

"Cycloalkyl" means mono- or bicyclic saturated carbocyclic rings, each of which having from 3 to 10 carbon atoms. The term also includes monocyclic rings fused to an aryl group in which the point of attachment is on the non-aromatic portion. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo [2.2.2]octanyl, tetrahydronaphthyl, dihydroindanyl, 3,3-spirohexylindoline, 5,6,7,8-tetrahydroquinoline, and the like.

"Aryl" means mono- or bicyclic aromatic rings containing only carbon atoms. The term also includes aryl group fused to a monocyclic cycloalkyl or monocyclic heterocycloalkyl group in which the point of attachment is on the aromatic portion. Examples of aryl include phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl) piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1,4-benzodioxanyl, and the like.

"Heteroaryl" means a mono- or bicyclic aromatic ring containing at least one heteroatom selected from N, O and S, with each ring containing 5- to 6 atoms. Examples of heteroaryl include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl,

furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, thienopyridinyl, and the like.

"Heterocycloalkyl" means mono- or bicyclic saturated rings containing at least one heteroatom selected from N, S and O, each of said ring having from 3 to 14 atoms in which the point of attachment may be carbon or nitrogen. The term also refers to bridged rings, and also includes monocyclic heterocycles fused to an aryl or heteroaryl group in which the point of attachment is on the non-aromatic portion. Examples of "heterocycloalkyl" include azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl,indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabiclyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1.]heptyl, 2,4-dizaobicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl, 3-azabicyclo[3,2.2]nonyl, 2H-pyrrolyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, 4,4-spiro[indoli-3,3-yl]piperidinyl, and the like. The term also includes partially unsaturated monocyclic rings that are not aromatic, such as 2- or 4-pyridones attached through the nitrogen or N-substituted-(1H,3H)-pyrimidine-2,4-diones (N-substituted uracils).

"Halogen" includes fluorine, chlorine, bromine and iodine.

Compounds of Formula I contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of Formula I.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed with compounds of Formula I.

Compounds of the Formula I may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example MeOH or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active amine as a resolving agent or on a chiral HPLC column.

Alternatively, any enantiomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that, as used herein, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

Compounds of this invention are antagonists of the MCH-1R receptor and as such are useful for the prevention and treatment of disorders or diseases associated with the MCH-1R receptor. Accordingly, another aspect of the present invention provides a method for the treatment (including prevention, alleviation, amelioration or suppression) of diseases or disorders or symptoms mediated by MCH-1R receptor binding and subsequent cell activation, which comprises administering to a mammal an effective amount of a compound of Formula I. Such diseases, disorders, conditions or symptoms are, for example, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, gall stones, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), binge eating disorders including bulimina, anorexia, mental disorders including manic depression, depression, schizophrenia, mood disorders, delirium, dementia, severe mental retardation, anxiety, stress, cognitive disorders, sexual function, reproductive function, kidney function, diuresis, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias including Parkinson's disease, Parkinson-like syndromes, Tourette's syndrome, Huntington's disease, epilepsy, improving memory function, and spinal muscular atrophy.

The utilities of the present compounds in these diseases or disorders may be demonstrated in animal disease models that have been reported in the literature. The following are examples of such animal disease models: a) suppression of food intake and resultant weight loss in rats (Life Sciences 1998, 63, 113-117); b) reduction of sweet food intake in marmosets (Behavioural Pharm. 1998, 9, 179-181); c) reduction of sucrose and ethanol intake in mice (Psychopharm. 1997, 132, 104-106); d) increased motor activity and place conditioning in rats (Psychopharm. 1998, 135, 324-332; Psychopharmacol. 2000, 151: 25-30) ; e) spontaneous locomotor activity in mice (J. Pharm. Exp. Ther. 1996, 277, 586-594).

The magnitude of prophylactic or therapeutic dose of a compound of Formula I will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound of Formula I and its route of administration. It will also vary according to the age, weight and response of the individual patient. In general, the daily dose range lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 50 mg per kg, and most preferably 0.1 to 10 mg per kg, in single or divided doses. On the other hand, it may be necessary to use dosages outside these limits in some cases.

For use where a composition for intravenous administration is employed, a suitable dosage range is from about 0.001 mg to about 25 mg (preferably from 0.01 mg to about 1 mg) of a compound of Formula I per kg of body weight per day and for cytoprotective use from about 0.1 mg to about 100 mg (preferably from about 1 mg to about 100 mg and more preferably from about 1 mg to about 10 mg) of a compound of Formula I per kg of body weight per day.

In the case where an oral composition is employed, a suitable dosage range is, e.g. from about 0.01 mg to about 100 mg of a compound of Formula I per day, preferably from about 0.1 mg to about 10 mg per day. For oral administration, the compositions are preferably provided in the form of tablets containing from 0.01 to 1,000 mg, preferably 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0 or 1000.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.

Another aspect of the present invention provides pharmaceutical compositions which comprises a compound of Formula I and a pharmaceutically acceptable carrier. The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.

Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to

salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and organic bases or acids.

The compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (aerosol inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulizers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery systems for inhalation are metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellants, such as fluorocarbons or hydrocarbons and dry powder inhalation (DPI) aerosol, which may be formulated as a dry powder of a compound of Formula I with or without additional excipients.

Suitable topical formulations of a compound of formula I include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like.

In practical use, the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets

and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out above, the compounds of Formula I may also be administered by controlled release means and/or delivery devices such as those described in U.S. Patent Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200 and 4,008,719.

Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 1 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 1 to about 500 mg of the active ingredient.

The following are examples of representative pharmaceutical dosage forms for the compounds of Formula I:

Injectable Suspension (I.M.) mg/mL	
Compound of Formula I	10
Methylcellulose	5.0
Tween 80	0.5
Benzyl alcohol	9.0
Benzalkonium chloride	1.0

Water for injection to a total volume of 1 mL

Tablet	mg/tablet
Compound of Formula I	25
Microcrystalline Cellulose	415
Povidone	14.0
Pregelatinized Starch	43.5
Magnesium Stearate	2.5
	500

Capsule	mg/capsule
Compound of Formula I	25
Lactose Powder	573.5
Magnesium Stearate	1.5
	600

Aerosol	Per canister
Compound of Formula I	24 mg
Lecithin, NF Liq. Conc.	1.2 mg
Trichlorofluoromethane, NF	4.025 g
Dichlorodifluoromethane, NF	12.15 g

Compounds of Formula I may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I. When a compound of Formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula I is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of Formula I.

It will be appreciated that for the treatment or prevention of eating disorders, including obesity, bulimia nervosa and compulsive eating disorders, a compound of the present invention may be used in conjunction with other anorectic agents.

The present invention also provides a method for the treatment or prevention of eating disorders, which method comprises administration to a patient in

need of such treatment an amount of a compound of the present invention and an amount of an anorectic agent, such that together they give effective relief.

Suitable anorectic agents of use in combination with a compound of the present invention include, but are not limited to, aminorex, amphechloral, amphetamine, benzphetamine, chlorphentermine, clobenzorex, cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine, dextroamphetamine, diethylpropion, diphemethoxidine, *N*-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex, fenproporex, fludorex, fluminorex, furfurylmethylamphetamine, levamfetamine, levophacetoperane, mazindol, mefenorex, metamfepramone, methamphetamine, norpseudoephedrine, pentorex, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picilorex and sibutramine; and pharmaceutically acceptable salts thereof.

A particularly suitable class of anorectic agent are the halogenated amphetamine derivatives, including chlorphentermine, cloforex, clortermine, dexfenfluramine, fenfluramine, picilorex and sibutramine; and pharmaceutically acceptble salts thereof.

Particularly preferred halogenated amphetamine derivatives of use in combination with a compound of the present invention include: fenfluramine and dexfenfluramine, and pharmaceutically acceptable salts thereof.

It will be appreciated that for the treatment or prevention of obesity, the compounds of the present invention may also be used in combination with a selective serotonin reuptake inhibitor (SSRI).

The present invention also provides a method for the treatment or prevention of obesity, which method comprises administration to a patient in need of such treatment an amount of a compound of the present invention and an amount of an SSRI, such that together they give effective relief.

Suitable selective serotonin reuptake inhibitors of use in combination with a compound of the present invention include: fluoxetine, fluvoxamine, paroxetine and sertraline, and pharmaceutically acceptable salts thereof.

The present invention also provides a method for the treatment or prevention of obesity, which method comprises administration to a patient in need of such treatment an amount of a compound of the present invention and an amount of growth hormone secretagogues such as those disclosed and specifically described in US Patent 5,536,716; melanocortin agonists such as Melanotan II; β-3 agonists such

as those disclosed and specifically described in patent publications WO94/18161, WO95/29159, WO97/46556, WO98/04526 and WO98/32753; 5HT-2 agonists; orexin antagonists; melanin concentrating hormone antagonists; galanin antagonists; CCK agonists; GLP-1 agonists; corticotropin-releasing hormone agonists; NPY-5 antagonists; CB1 modulators, such as N-(1-piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR141716A), and those described in US Patents US 5,624,941 and US 6,028,084, PCT Application Nos. WO98/43636, WO98/31227, WO98/41519, WO98/37061, WO00/10967, WO00/10968, WO97/29079, WO99/02499 and WO98/43635, and EPO Application No. EP-658546; and Y1 antagonists, such that together they give effective relief.

As used herein "obesity" refers to a condition whereby a mammal has a Body Mass Index (BMI), which is calculated as weight per height squared (kg/m^2), of at least 25.9. Conventionally, those persons with normal weight, have a BMI of 19.9 to less than 25.9.

It will be appreciated that for the treatment or prevention of obesity, the compounds of the present invention may also be used in combination with histamine receptor-3 (H3) modulators, CB1 cannabinoid receptor antagonists or inverse agonists, and/or phosphodiesterase-3B (PDE3B) inhibitors.

The obesity described herein may be due to any cause, whether genetic or environmental. Examples of disorders that may result in obesity or be the cause of obesity include overeating and bulimia, polycystic ovarian disease, craniopharyngioma, the Prader-Willi Syndrome, Frohlich's syndrome, Type II diabetes, GH-deficient subjects, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity or a decrease in resting energy expenditure as a percentage of total fat-free mass, e.g., children with acute lymphoblastic leukemia.

"Treatment" (of obesity) refers to reducing the BMI of the mammal to less than about 25.9, and maintaining that weight for at least 6 months. The treatment suitably results in a reduction in food or calorie intake by the mammal.

"Prevention" (of obesity) refers to preventing obesity from occurring if the treatment is administered prior to the onset of the obese condition. Moreover, if treatment is commenced in already obese subjects, such treatment is expected to prevent, or to prevent the progression of, the medical sequelae of obesity, such as, e.g., arteriosclerosis, Type II diabetes, polycystic ovarian disease, cardiovascular

diseases, osteoarthritis, dermatological disorders, hypertension, insulin resistance, hypercholesterolemia, hypertriglyceridemia, and cholelithiasis.

Excessive weight is a contributing factor to different diseases including hypertension, diabetes, dyslipidemias, cardiovascular disease, gall stones, osteoarthritis and certain forms of cancers. Bringing about a weight loss can be used, for example, to reduce the likelihood of such diseases and as part of a treatment for such diseases. Weight reduction can be achieved by antagonizing MCH-1R receptor activity to obtain, for example, one or more of the following effects: reducing appetite, increasing metabolic rate, reducing fat intake or reducing carbohydrate craving.

Other compounds that may be combined with a compound of Formula I, either administered separately or in the same pharmaceutical compositions, for the treatment of diabetes and other sequelae of excessive weight include, but are not limited to:

(a) insulin sensitizers including (i) PPARγ agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, BRL49653 and the like), and compounds disclosed in WO97/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin;

(b) insulin or insulin mimetics;

(c) sulfonylureas, such as tolbutamide and glipizide;

(d) α-glucosidase inhibitors (such as acarbose),

(e) cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, and other statins), (ii) sequestrants (cholestyramine, colestipol and a dialkylaminoalkyl derivatives of a cross-linked dextran), (ii) nicotinyl alcohol nicotinic acid or a salt thereof, (iii) proliferator-activater receptor α agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (iv) inhibitors of cholesterol absorption for example beta-sitosterol and (acyl CoA:cholesterol acyltransferase) inhibitors for example melinamide, (v) probucol, (vi) vitamin E, and (vii) thyromimetics;

(f) PPARδ agonists, such as those disclosed in WO97/28149;

(g) antiobesity compounds, such as fenfluramine, dexfenfluramine, phentermine, sibutramine, orlistat, or β3 adrenergic receptor agonists;

(h) feeding behavior modifying agents, such as neuropeptide Y antagonists (e.g. neuropeptide Y5) such as those disclosed in WO 97/19682, WO 97/20820, WO 97/20821, WO 97/20822 and WO 97/20823;

(i) PPARα agonists such as described in WO 97/36579 by Glaxo;

(j) PPARγ antagonists as described in WO97/10813;

(k) serotonin reuptake inhibitors such as fluoxetine and sertraline;

(l) growth hormone secretagogues such as MK-0677.

It will be appreciated that for the treatment or prevention of stress, a compound of the present invention may be used in conjunction with other anti-stress agents, such as anti-anxiety agents. Suitable classes of anti-anxiety agents include benzodiazepines and 5-HT_{1A} agonists or antagonists, especially 5-HT_{1A} partial agonists, and corticotropin releasing factor (CRF) antagonists.

Suitable benzodiazepines include: alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam, and pharmaceutically acceptable salts thereof.

Suitable 5-HT_{1A} receptor agonists or antagonists include, in particular, the 5-HT_{1A} receptor partial agonists buspirone, flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptable salts thereof.

Suitable CRF antagonists include the 4-tetrahydropyridylpyrimidine derivatives disclosed in US 6,187,781; the aryloxy and arylthio-fused pyridine and pyrimidine derivatives disclosed in US 6,124,300; the arylaminofused pyrimidine derivatives disclosed in US 6,107,300; the pyrazole and pyrazolopyrimidine derivatives disclosed in US 5,705,646, US 5,712,303, US 5,968,944, US 5,958,948, US 6,103,900 and US 6,005,109; the tetrahydropteridine derivatives disclosed in US 6,083,948; the benzoperimidine carboxylic acid derivatives disclosed in US 5,861,398; the substituted 4-phenylaminothiazol derivatives disclosed in US 5,880,135; the cyclic CRF analogs disclosed in US5,493,006, US 5,663,292 and US 5,874,227; and the compounds disclosed in US 5,063,245, US 5,245,009, US 5,510,458 and US 5,109,111; as well as compounds described in International Patent Specification Nos. WO 94/13643, WO 94/13644, WO 94/13661, WO 94/13676 and WO 94/13677.

As used herein, the term "substance abuse disorders" includes substance dependence or abuse with or without physiological dependence. The substances associated with these disorders are: alcohol, amphetamines (or amphetamine-like substances), caffeine, cannabis, cocaine, hallucinogens, inhalants,

nicotine, opioids, phencyclidine (or phencyclidine-like compounds), sedative-hypnotics or benzodiazepines, and other (or unknown) substances and combinations of all of the above.

In particular, the term "substance abuse disorders" includes drug withdrawal disorders such as alcohol withdrawal with or without perceptual disturbances; alcohol withdrawal delirium; amphetamine withdrawal; cocaine withdrawal; nicotine withdrawal; opioid withdrawal; sedative, hypnotic or anxiolytic withdrawal with or without perceptual disturbances; sedative, hypnotic or anxiolytic withdrawal delirium; and withdrawal symptoms due to other substances. It will be appreciated that reference to treatment of nicotine withdrawal includes the treatment of symptoms associated with smoking cessation.

Other "substance abuse disorders" include substance-induced anxiety disorder with onset during withdrawal; substance-induced mood disorder with onset during withdrawal; and substance-induced sleep disorder with onset during withdrawal.

Similarly, compound of Formula I, will be useful as a partial or complete substitute for conventional pain relievers in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for modulating the perception of pain comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including acetaminophen or phenacetin, or a cyclooxygenase-2 (COX-2) inhibitor; a potentiator including caffeine; a prostaglandin including misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol: a diuretic; a sedating or non-sedating antihistamine. Examples of cyclooxygenase-2 selective inhibitors include rofecoxib (VIOXX®, see U.S. Patent No. 5,474,995), etoricoxib (ARCOXIA™ see U.S. Patent No. 5,861,419), celecoxib (CELEBREX®, see U.S. Patent No. 5,466,823), valdecoxib (see U.S. No. 6,633,272), parecoxib (see U.S. No. 5,932,598), COX-189 (Novartis), BMS347070 (Bristol Myers Squibb), tiracoxib (JTE522, Japan Tobacco), ABT963 (Abbott), CS502 (Sankyo) and GW406381 (GlaxoSmithKline). Other examples of cyclooxygenase-2 inhibitors compounds are disclosed in U.S. Patent No. 6,020,343. In addition the invention encompasses a method of treating pain comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of the compound of Formula I, optionally co-

administered with one or more of such ingredients as listed immediately above.

"Male sexual dysfunction" includes impotence, loss of libido, and erectile dysfunction. "Erectile dysfunction" is a disorder involving the failure of a male mammal to achieve erection, ejaculation, or both. Symptoms of erectile dysfunction include an inability to achieve or maintain an erection, ejaculatory failure, premature ejaculation, or inability to achieve an orgasm. An increase in erectile dysfunction and sexual dysfunction can have numerous underlying causes, including but not limited to (1) aging, (b) an underlying physical dysfunction, such as trauma, surgery, and peripheral vascular disease, and (3) side-effects resulting from drug treatment, depression, and other CNS disorders. "Female sexual dysfunction" can be seen as resulting from multiple components including dysfunction in desire, sexual arousal, sexual receptivity, and orgasm related to disturbances in the clitoris, vagina, periurethral glans, and other trigger points of sexual function. In particular, anatomic and functional modification of such trigger points may diminish the orgasmic potential in breast cancer and gynecologic cancer patients. Treatment of female sexual dysfunction with an MC-4 receptor agonist can result in improved blood flow, improved lubrication, improved sensation, facilitation of reaching orgasm, reduction in the refractory period between orgasms, and improvements in arousal and desire. In a broader sense, "female sexual dysfunction" also incorporates sexual pain, premature labor, and dysmenorrhea.

For the treatment of male and female sexual dysfunction, the compounds of the present invention may be employed in combination with a compound selected from a type V cyclic-GMP-specific phosphodiesterase (PDE-V) inhibitor, such as sildenafil and IC-351 or a pharmaceutically acceptable salt thereof; an alpha-adrenergic receptor antagonist, such as phentolamine and yohimbine or a pharmaceutically acceptable salt thereof; or a dopamine receptor agonist, such as apomorphine or a pharmaceutically acceptable salt thereof.

Suitable antipsychotic agents of use in combination with a compound of the present invention for the treatment of schizophrenia include the phenothiazine, thioxanthene, heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine and indolone classes of antipsychotic agent. Suitable examples of phenothiazines include chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine. Suitable examples of thioxanthenes include chlorprothixene and thiothixene. Suitable examples of dibenzazepines include clozapine and olanzapine. An example of a butyrophenone is haloperidol. An

example of a diphenylbutylpiperidine is pimozide. An example of an indolone is molindolone. Other antipsychotic agents include loxapine, sulpiride and risperidone. It will be appreciated that the antipsychotic agents when used in combination with a CB1 receptor modulator may be in the form of a pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidol decanoate, loxapine succinate and molindone hydrochloride. Perphenazine, chlorprothixene, clozapine, olanzapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form.

Other classes of antipsychotic agent of use in combination with a compound of the present invention include dopamine receptor antagonists, especially D2, D3 and D4 dopamine receptor antagonists, and muscarinic M1 receptor agonists. An example of a D3 dopamine receptor antagonist is the compound PNU-99194A. An example of a D4 dopamine receptor antagonist is PNU-101387. An example of a muscarinic M1 receptor agonist is xanomeline.

Another class of antipsychotic agent of use in combination with a CB1 receptor modulator is the 5-HT_{2A} receptor antagonists, examples of which include MDL100907 and fananserin. Also of use in combination with a compound of the present invention are the serotonin dopamine antagonists (SDAs) which are believed to combine 5-HT_{2A} and dopamine receptor antagonist activity, examples of which include olanzapine and ziperasidone.

It will be appreciated that for the treatment of depression or anxiety, a compound of the present invention may be used in conjunction with other anti-depressant or anti-anxiety agents.

Suitable classes of anti-depressant agents include norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, α-adrenoreceptor antagonists, neurokinin-1 receptor antagonists and atypical anti-depressants.

Suitable norepinephrine reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics. Suitable examples of tertiary amine tricyclics include: amitriptyline, clomipramine, doxepin, imipramine and

trimipramine, and pharmaceutically acceptable salts thereof. Suitable examples of secondary amine tricyclics include: amoxapine, desipramine, maprotiline, nortriptyline and protriptyline, and pharmaceutically acceptable salts thereof.

Suitable selective serotonin reuptake inhibitors include those described *supra.*

Suitable monoamine oxidase inhibitors include: isocarboxazid, phenelzine, tranylcypromine and selegiline, and pharmaceutically acceptable salts thereof.

Suitable reversible inhibitors of monoamine oxidase include: moclobemide, and pharmaceutically acceptable salts thereof.

Suitable serotonin and noradrenaline reuptake inhibitors of use in the present invention include: venlafaxine, and pharmaceutically acceptable salts thereof.

Suitable CRF antagonists include those compounds described hereinabove.

Suitable atypical anti-depressants include: bupropion, lithium, nefazodone, trazodone and viloxazine, and pharmaceutically acceptable salts thereof.

Suitable classes of anti-anxiety agents include benzodiazepines and 5-HT_{1A} agonists or antagonists, especially 5-HT_{1A} partial agonists, and corticotropin releasing factor (CRF) antagonists.

The neurokinin-1 receptor antagonist may be peptidal or non-peptidal in nature, however, the use of a non-peptidal neurokinin-1 receptor antagonist is preferred. In a preferred embodiment, the neurokinin-1 receptor antagonist is a CNS-penetrant neurokinin-1 receptor antagonist. In addition, for convenience the use of an orally active neurokinin-1 receptor antagonist is preferred. To facilitate dosing, it is also preferred that the neurokinin-1 receptor antagonist is a long acting neurokinin-1 receptor antagonist. An especially preferred class of neurokinin-1 receptor antagonists of use in the present invention are those compounds which are orally active and long acting.

Neurokinin-1 receptor antagonists of use in the present invention are fully described, for example, in U.S. Patent Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595, 5,459,270, 5,494,926, 5,496,833, 5,637,699; European Patent Publication Nos. EP 0 360 390, 0 394 989, 0 428 434, 0 429 366, 0 430 771, 0 436 334, 0 443 132, 0 482 539, 0 498 069, 0 499 313, 0 512 901, 0 512 902, 0 514 273, 0 514 274, 0 514 275, 0 514 276, 0 515 681, 0 517 589, 0 520 555, 0 522 808, 0 528

495, 0 532 456, 0 533 280, 0 536 817, 0 545 478, 0 558 156, 0 577 394, 0 585 913,0 590 152, 0 599 538, 0 610 793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0 707 006, 0 708 101, 0 709 375, 0 709 376, 0 714 891, 0 723 959, 0 733 632 and 0 776 893; PCT International Patent Publication Nos. WO 90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151, 92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 92/22569, 93/00330, 93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116, 93/10073, 93/14084, 93/14113, 93/18023, 93/19064, 93/21155, 93/21181, 93/23380, 93/24465, 94/00440, 94/01402, 94/02461, 94/02595, 94/03429, 94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/08997, 94/10165, 94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767, 94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309, 95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549, 95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129, 95/19344, 95/20575, 95/21819, 95/22525, 95/23798, 95/26338, 95/28418, 95/30674, 95/30687, 95/33744, 96/05181, 96/05193, 96/05203, 96/06094, 96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304, 96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553, 97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/19084, 97/19942, 97/21702, and 97/49710; and in British Patent Publication Nos. 2 266 529, 2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293 169, and 2 302 689.

Specific neurokinin-1 receptor antagonists of use in the present invention include:

(±)-(2R3R,2S3S)-N-{[2-cyclopropoxy-5-(trifluoromethoxy)-phenyl]methyl}-2-phenylpiperidin-3-amine;

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)-3-(S)-phenyl-morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;

(3S,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

(3R,5R,6S)-3-[2-cyclopropoxy-5-(trifluoromethoxy)phenyl]-6-phenyl-1-oxa-7-aza-spiro[4.5]decane;

2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)-4-(1,2,4-triazol-3-yl)methylmorpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxyphosphoryl-1H-1,2,4-triazolo)methyl)morpholine;

2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(1-monophosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine;

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N-dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;

or a pharmaceutically acceptable salt thereof.

Suitable benzodiazepines include those described previously herein.

Suitable 5-HT_{1A} receptor agonists or antagonists include, in particular, those described *supra*.

For the treatment of autism, the compounds of the present invention may be used in combination with butyrophenones.

For the treatment of Parkinson's disease and Parkinson-like syndromes, the compounds of the present invention may be used in combination with levodopa, carbidopa/levodopa, amantadine, bromocryptine and other ergot alkaloids, anticholinergic medications such as benztropine, trihexyphenidyl, antihistamines such as diphenhydramine and orphenadrine, mild sedatives, tricyclic antidepressants such as amitriptiline and others described *supra*, and propanolol.

For the treatment of Huntingdon's Chorea, the compounds of the present invention may be used in combination with phenothiazine, chlorpromazine, and butyrophenone neuroleptics such as haloperidol or reserpine.

For the treatment of epilepsy, the compounds of the present invention may be used together with anticonvulsants such as penytoin, phenobarbital, primidone, carbamazepine, trimethadione, clonazepam, valproate and ethosuximide

MCH-1R antagonist compounds can be provided in kit. Such a kit typically contains an active compound in dosage forms for administration. A dosage form contains a sufficient amount of active compound such that a beneficial effect can be obtained when administered to a patient during regular intervals, such as 1 to 6 times a day, during the course of 1 or more days. Preferably, a kit contains instructions indicating the use of the dosage form for weight reduction (*e.g.*, to treat obesity or overweight) or stress reduction, and the amount of dosage form to be taken over a specified time period.

The method of treatment of this invention comprises a method of treating melanin concentrating hormone receptor mediated diseases by administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of this invention that selectively antagonizes the MCH-1R receptor in preference to the other G-protein coupled receptors. In particular, the present invention comprises a method of treating MCR-1R receptor subtype mediated diseases by administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of this invention that selectively antagonizes the MCH-1R receptor.

The weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the Formula I is combined with a β-3 agonist the weight ratio of the compound of the Formula I to the β-3 agonist will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

The compounds of Formula I of the present invention can be prepared according to the procedures of the following Schemes and Examples, using appropriate materials and are further exemplified by the following specific examples. Moreover, by utilizing the procedures described with the disclosure contained herein, one of ordinary skill in the art can readily prepare additional compounds of the

present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The Examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. The instant compounds are generally isolated in the form of their pharmaceutically acceptable salts, such as those described previously hereinabove. The free amine bases corresponding to the isolated salts can be generated by neutralization with a suitable base, such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide, and potassium hydroxide, and extraction of the liberated amine free base into an organic solvent followed by evaporation. The amine free base isolated in this manner can be further converted into another pharmaceutically acceptable salt by dissolution in an organic solvent followed by addition of the appropriate acid and subsequent evaporation, precipitation, or crystallization. All temperatures are degrees Celsius unless otherwise noted. Mass spectra (MS) were measured by electron-spray ionization.

The phrase "standard peptide coupling reaction conditions" means coupling a carboxylic acid with an amine using an acid activating agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl (EDC), 1,3-dicyclohexylcarbodiimide (DCC), and benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) in an inert solvent such as dichloromethane in the presence of a catalyst such as 4-dimethylaminopyridine (DMAP) or 1-hydroxybenzotriazole hydrate (HOBT). The use of protecting groups for the amine, carboxylic acid or other functionalities to facilitate the desired reaction and minimize undesired reactions is well documented. Conditions required to remove protecting groups are found in standard textbooks such as Greene, T. and Wuts, P. G. M., *Protective Groups in Organic Synthesis*, John Wiley & Sons, Inc., New York, NY, 1991. Benzyloxycarbonyl (CBZ) and t-butyloxycarbonyl (BOC) protecting groups are commonly used protecting groups in organic synthesis, and conditions for their removal are known to those skilled in the art. For example, CBZ may be removed by catalytic hydrogenation in the presence of a noble metal or its oxide such as palladium on activated carbon in a protic solvent such as methanol or ethanol. In cases where catalytic hydrogenation is contraindicated due to the presence of other potentially reactive functionalities, removal of CBZ groups can also be achieved by treatment with a solution of hydrogen bromide in acetic acid or by treatment with a mixture of

trifluoroacetic acid (TFA) and dimethylsulfide. Removal of BOC protecting groups is carried out with a strong acid, such as trifluoroacetic acid, hydrochloric acid, or hydrogen chloride gas, in a solvent such as methylene chloride, methanol, or ethyl acetate.

Abbreviations Used in the Description of the Preparation of the Compounds of the Present Invention and Biological Assays:

BOC (boc)	t-butyloxycarbonyl
BOP	benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
BSA	Bovine serum albumin
Bu	butyl
calc.	calculated
CBZ (Cbz)	benzyloxycarbonyl
c-hex	cyclohexyl
c-pen	cyclopentyl
c-pro	cyclopropyl
DCC	1,3-dicyclohexylcarbodiimide
DIEA	diisopropylethylamine
DMAP	4-dimethylaminopyridine
DMF	N,N-dimethylformamide
ECB buffer	Extra-cellular buffer: 140nM NaCl, 20 nM KCl, 20mM HEPES-NaOH pH 7.4, 5mM glucose, 1mM $MgCl_2$, 1mM $CaCl_2$, 0.1 mg/mL BSA
EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl
EDTA	Ethylenediamine tetraacetic acid
eq.	equivalent(s)
ES-MS	electron spray ion-mass spectroscopy
Et	ethyl
EtOAc	ethyl acetate
h	hour
HEPES	4-(2-hydroxyethyl)piperazine-1-ethane sulfonic acid
HOAc	acetic acid
HOBt	1-hydroxybenzotriazole hydrate
HPLC	high performance liquid chromatography

Me	methyl
MF	molecular formula
MS	mass spectrum
Ms	methanesulfonyl
$POCl_3$	Phosphorous oxychloride
Ph	phenyl
Pr	propyl
prep.	prepared
r.t.	room temperature
TEA	triethylamine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin-layer chromatography.

General preparation of 4-amino-6-substituted quinoline intermediates 7

Scheme A



There are many known preparation of quinolines available to those skilled in the art. Scheme A illustrates the preparation of substituted quinolines utilized for the present invention and follows closely to published procedures reported by Lanza et al. *J. Med. Chem.* **1992**, *35*, 252- 258. Heating of substituted anilines **1**, in particular, 4-

substituted anilines, with a variety of substituted ketoesters 2 with an acid catalyst such as hydrochloric or p-toluenesulfonic acid in an appropriate solvent for several hours affords 3-(substituted phenyl) ester intermediates 3. Isolation of these intermediates 3 or simply further heating crude intermediates 3 at higher temperature in an inert solvent such as diphenyl ether provides substituted 4-hydroxyquinoline intermediates 5. Alternatively, heating aniline starting materials 1 and alkynyl ester intermediates 4 with an acid catalyst provides the intermediates 3 which may be converted in like fashion (with or without isolation) by further heating to quinoline intermediates 5. Alkylation of the 4-hydroxyl group of intermediates 5 under a variety of conditions such as treatment of the 4-hydroxyquinoline intermediates 5 with dimethylsulfate or similar alkylating agents in toluene under reflux affords 4-alkoxyquinoline intermediates 6. Further substitution of the 4-position occurs by heating 4-alkoxyquinoline intermediates 6 (R_1 = Me) with an ammonium salt such as ammonium acetate to afford 4-aminoquinoline intermediates 7. Alternatively, heating 4-alkoxyquinoline intermediates 6 (R_1 = Me) in a sealed tube with an ammonia solution, substituted amine (neat or in an appropriate solvent) or an amine salt and appropriate base provides 4-aminoquinoline intermediates 7. Standard functional group manipulation of substituents of the quinoline ring system known to those skilled in the art provides compounds 7 of the present invention.

General preparation of *N*-substituted 4-aminoquinoline intermediates 9

Scheme B



An improved preparation of *N*-substituted 4-aminoquinoline intermediates **9** is available as described in Scheme B. Substituted 4-hydroxyquinoline intermediates **5** may be converted to 4-chloroquinoline intermediates **8** (X = Cl) by a variety of methods such as treatment with a chlorinating reagent such as phosphorous oxychloride in refluxing toluene. This transformation creates an improved leaving group at the 4-position of the quinoline ring. Similarly, the 4-hydroxyl group of intermediate **5** may be converted by those skilled in the art to other known improved leaving groups, for example, but not limited to, fluoride, bromide, iodide, methanesulfonate or trifluoromethanesulfonate. Heating of the 4-chloroquinolines **8** (X = Cl) or similar quinoline intermediates **8** with a leaving group at the 4-position with ammonia, a primary or secondary amine in an appropriate solvent provides the *N*-substituted 4-aminoquinoline intermediates **9**. Ammonia or volatile amines may be heated neat or with an appropriate solvent in a sealed tube to provide these intermediates. Alternatively, amine salts combined with an appropriate tertiary amine base or inorganic base such as sodium bicarbonate may provide the desired substituted aminoquinoline intermediates **9**. Standard functional group manipulation of substituents of the quinoline ring system known to those skilled in the art provides compounds **9** of the present invention.

General preparation of 4,6-diaminoquinoline intermediates

Scheme C



10 **11** **12** **11**

4,6-Diaminoquinoline intermediates **11** may be prepared as described in Scheme C. 4,6-Diaminoquinoline intermediates **10** containing protected 6-amino groups may be

converted to the 6-amino derivatives **11** by removal of the protecting groups using methods known to those skilled in the art as described above (eq. 1). Such protecting groups may be carboxamides such as acetyl groups or carbamate protecting groups such as BOC–group or CBZ group, for example. Alternatively 4-amino-6-nitroquinoline intermediates **12** may be converted to 4,6-diaminoquinoline intermediates **11** by reduction of the nitro group using a variety of methods known to those skilled in the art (eq. 2). For example, treatment of the nitro group of intermediates **12** with chemical reducing agents such as tin (II) chloride, ferric chloride, hydrazine system in the presence of carbon, or lithium aluminium hydride may produce amino groups of intermediates **11**. Similarly catalytic reduction of nitro groups of intermediates **12** with hydrogen in the presence of a noble metal catalyst such as palladium on carbon or platinum oxide may provide the desired amino compound **11**. Choice of reducing conditions by those skilled in the art may be dictated by other functional groups present in the intermediates **12** which are contraindicated to the nitro group reducing conditions. 6-Nitroquinoline intermediates **12** may be prepared by those skilled in the art from appropriate substituted nitroanilines and other appropriate starting materials using the synthetic route outlined in Schemes A and B.

General preparation of N-(4-aminoquinolin-6-yl)carboxamides

Scheme D







Compounds of the present invention may be prepared by those skilled in the art by reaction of the 4,6-diaminoquinoline intermediates **11** with carboxylic acid derivatives **13** under a variety of conditions to provide the desired N-(4-aminoquinolin-6-yl)carboxamides **15** as described in Scheme D. Treatment of carboxylic acid intermediates **13** with oxalyl chloride with a catalytic amount of N,N-dimethylformamide (DMF) in an inert solvent such as methylene chloride under an inert atmosphere provides the corresponding acid chloride intermediates **14**. Similarly, treatment of the carboxylic acid intermediates **13** with thionyl chloride in toluene at reflux provides acid chloride intermediates **14**. Reaction of the 4,6-diaminoquinoline intermediates **11** with the acid chloride intermediates **14** in acetic acid solvent provides the desired N-(4-aminoquinolin-6-yl)carboxamides **15**, which may be isolated as salts from the reaction mixture by filtration or other methods known to those skilled in the art. Alternatively, products **15** may be purified by a variety of techniques known to those skilled in the art such as (but not limited to) preparative thin layer chromatography (tlc), HPLC, reverse phase HPLC or column chromatography on a variety of adsorbents such as silica gel or alumina. Similarly, reaction of the 4,6-diaminoquinoline intermediates **11** with acid chloride derivatives

14 in the presence of a tertiary amine or other base in an inert solvent such as methylene chloride affords the desired N-(4-aminoquinolin-6-yl)carboxamides **15**. Alternatively, N-(4-aminoquinolin-6-yl)carboxamides **15** may be prepared directly from carboxylic acid derivatives **13** and the 4,6-diaminoquinoline intermediates **11** using a variety of standard peptide coupling reagents as described earlier, such as EDC and DMAP, in an inert solvent such as methylene chloride followed by standard workup and purification as described earlier.

Carboxylic acid intermediates **13** are available from a wide range of commercial sources. Alternatively, carboxylic acid derivatives **13** may be prepared by a variety of methods known to those skilled in the art such as, but not limited to, oxidation of other functional groups, carbonylation, saponification of ester intermediates, or deprotection of protected carboxylic acids. Homologated carboxylic acids may be prepared from carboxylic acids by conversion to the corresponding carboxaldehyde intermediates (or directly from available carboxaldehydes) followed by homologation utilizing stabilized Wittig or Horner-Emmons reagents to provide unsaturated acid or ester intermediates. These intermediates may be converted directly to carboxylic acid derivatives **13**. Alternatively, the resulting olefin may be functionalized or reduced to the saturated derivative by a variety of conditions known to those skilled in the art such as by catalytic hydrogenation in the presence of a noble metal catalyst such as palladium on carbon or platinum oxide. These saturated intermediates may in turn be converted to carboxylic acid derivatives **13**.

General preparation of 4-aminoquinolin-6-carboxamide and related derivatives

Scheme E



eq. 1

eq. 2

4-Aminoquinolin-6-carboxamide derivatives **17** may be prepared as outlined in Scheme E from 4-amino-6-substituted quinoline derivatives **16** described in Scheme A, wherein the 6-substituent is a carboxylic acid or protected carboxylic acid derivative. Treatment of the carboxylic acid intermediate **16** (R_7 = H) directly with an amine under standard peptide coupling conditions such as EDC and DMAP in an inert solvent such as methylene chloride provides the desired quinoline-6-carboxamides **17**. Similarly, removal of the protecting group of the carboxylic acid derivative **16** followed by carboxamide formation affords the quinoline-6-carboxamides **17**. Homologated analogs may be prepared by homologation of the carboxylic acid intermediates **16** or other intermediates derived thereof using methods known to those skilled in the art such as but not limited to the Arndt-Eistert homologation, or by the sequence of conversion of the acid to the alcohol, leaving group formation, cyanide displacement followed by hydrolysis to the homologated carboxylic acid intermediates **18**. Similarly, the carboxylic acid intermediates **16** may be converted to the carboxaldehyde intermediate followed by Wittig or Horner-Emmons homologation and subsequent functional group manipulation as described earlier. Alternatively, homologated carboxylic acid intermediates **18** may be prepared by those skilled in the art from substituted aniline intermediates containing the required homologated acid and other appropriate starting materials using the quinoline synthesis outlined in Schemes A and B. Finally, theses homologated carboxylic acid intermediates **18** may be converted by standard peptide coupling techniques such as

those described in Scheme D, with a variety of amines to homologated carboxamide derivatives **19**.

General preparation of 4-amino-6-heterocycle substituted quinoline derivatives and related analogs

Scheme F



Quinoline derivatives containing heterocycle groups at the 6-position in place of 4-aminoquinoline-6-carboxamide or related analogs or in place of N-(4-aminoquinoline-6-yl)carboxamide or related analogs may be prepared as outlined in Scheme F from quinoline-6-carboxylic acid derivatives **18** or related homologs. Oxadiazolyl or related heterocyclic derivatives are known to be useful replacements for carboxamide, urea, sulfonamide and other hydrogen bond donating functional groups. Removal of these hydrogen bonding groups may increase water solubility, remove waters of hydration or vary other physical chemical properties that may improve pharmacokinetic parameters such as oral absorption, oral bioavailability or metabolic disposition of these compounds.

These heterocycle substituted quinoline derivatives may be prepared by a variety of methods known to those skilled in the art. For example, treatment of quinolin-6-carboxylic acid intermediates **18** with EDC and DMAP in the presence of an amidoxime derivative **20** followed by heating at reflux in an inert solvent such 1,4-dioxane or 1,2-dimethoxyethane provides (3-substituted-1,2,4-oxadiazol-5yl)quinolin-4-yl amine derivatives **21**. Similarly, homologated 4-aminoquinolin-6-yl carboxylic

acid intermediates **18** provide the related homologated (3-substituted-1,2,4-oxadiazol-5yl)quinolin-4-yl amine analogs **21**. Amidoxime intermediates **20** may be commercially available or may be prepared from nitrile intermediates by treatment with hydroxylamine hydrochloride in the presence of an inorganic base such as sodium bicarbonate in an alcoholic solvent.

Isomeric 6-(5-substituted-1,2,4-oxadiazol-3yl)quinolin-4-amines **23** may be prepared in a similar fashion from 4-aminoquinoline-6-nitrile intermediates **22** or related homologs. 4-Aminoquinoline-6-nitrile intermediates **22** may be prepared as outlined is Scheme A directly from nitrile substituted anilines. Alternatively, quinoline-6-carboxylic acid derivatives **18** may be converted to quinoline-6-carboxamide derivatives as described earlier followed by dehydration using a variety of methods known to those skilled in the art. Reaction of the nitrile intermediates **22** with hydroxylamine as described above affords the corresponding amidoxime intermediates. Coupling of the amidoxime intermediates with a carboxylic acid derivative **13** in the presence of EDC and DMAP followed by heating in an inert solvent provides the isomeric (5-substituted-1,2,4-oxadiazol-3yl)quinolin-4-amine analogs **23**. Similarly, homologated 4-aminoquinolin-6-yl-carboxylic acid intermediates **18** may be converted homologated nitrile intermediates **22** then by analogy to related (5-substituted-1,2,4-oxadiazol-3yl)quinolin-4-amine homologs **23**.

Scheme G



Preparation of further 6-substituted-4,6-diaminoquinoline derivatives is outlined in Scheme G. Simple chemical reduction of the carboxamide group of N-(4-aminoquinolin-6-yl)carboxamide intermediates **15** (eq. 1) and 4-aminoquinolin-6-carboxamide intermediates **19** (eq. 2) by a variety of reducing agents known to those skilled in the art, such as borane derivatives or lithium aluminium hydride, affords the 6-substituted-4,6-diaminoquinoline derivatives **24** and **25** respectively. Alternatively, carboxylic acid intermediates **18** may be converted to amine derivatives **26** by rearrangement reactions such as the Curtius reaction or related rearrangement reactions known to those skilled in the art. Hydrolysis of amine intermediates or removal of protecting groups resulting from the rearrangement reactions may provide the desired 4,6-diaminoquinoline derivatives **26**.

Scheme H



eq. 1



eq. 2

Similarly, other quinolin-4,6-diamine derivatives **27** may be converted to quinolin-4,6-diamine derivatives **26** by reductive amination with a carboxaldehyde or ketone derivative (Scheme H, eq. 1) or by first, carboxamide formation, followed by further reduction of the carboxamide intermediate to the quinolin-4,6-diamine derivatives **26**. Alternatively, (4-aminoquinolin-6-yl)carboxaldehyde intermediates **28** (R_7 = H, eq. 2) or related ketone intermediates (R_7 = C, eq. 2) may be converted to quinolin-4,6-diamine derivatives **29** by reductive amination with a variety of amines under a variety of conditions known to those skilled in the art such as sodium cyanoborohydride in the presence of a drying agent and acid buffer in an appropriate

solvent such as methanol. (4-Aminoquinolin-6-yl)carboxaldehyde intermediates **28** or related homologated intermediates may be prepared by a variety of methods known to those skilled in the art. For example, oxidation of related alcohol derivatives or reduction of carboxylic acid or related carboxamide ester or nitrile derivatives may provide the desired (4-aminoquinolin-6-yl)carboxaldehyde intermediates **28** or related homologs. Similarly, (4-aminoquinolin-6-yl)ketone intermediates **28** or related homologs may be prepared from above intermediates by many methods known to those skilled in the art. Alternatively, quinoline carboxaldehyde or ketone intermediates **28** may be reduced to the corresponding alcohol intermediates, subsequent leaving group formation then displacement with a suitable amine or surrogate amine nucleophile. Further functional group manipulation or protecting group removal may provide quinolin-4,6-diamine derivatives **29**.

Scheme I



27 **30**

Further derivatives of amine **27** may be prepared by reaction of the amine with a variety of electrophiles such as carboxylic acids or their acid chlorides, isocyanates, carbamoyl chlorides, ketenes, chloroformates, sulfonic acids or their sulfonyl chloride to provide further derivatives of the present invention of the general structure **30** (Scheme I).

The following Examples are provided to illustrate the invention and are not to be construed as limiting the scope of the invention in any manner.

EXAMPLE 1



(2E)-N-(4-Amino-2-propylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide

Step A: Preparation of ethyl (2*E*)- and (2*Z*)-3-{[4-(acetylamino)phenyl]amino}hex-2-enoate

A mixture of N-(4-aminophenyl)acetamide (9.7g, 65mmol), ethyl 3-oxohexanoate (10g, 65mmol) and 2 drops conc. HCl in 30mL ethanol was heated at reflux overnight. After approximately 18h, the reaction mixture was cooled to r.t. and the solids collected by filtration. The solids were washed with methanol and air dried to afford the crude product as a solid, which was used without further purification in the subsequent reaction.

Step B: Preparation of *N*-(4-hydroxy-2-propylquinolin-6-yl)acetamide

The crude product (9.0g) from Step A was mixed with 50mL of diphenylether. The mixture was heated with a heating mantle at 260° for 2h then cooled to r.t. The resulting solid was collected by filtration, washed with EtOAc to give a grey solid, which was used directly in the next step.

Step C: Preparation of *N*-(4-methoxy-2-propylquinolin-6-yl)acetamide

The crude product (5.9g) from Step B and dimethylsulfate (4.6mL, 48mmol) were mixed in toluene and heated at reflux for 2.5h. The reaction mixture was cooled to r.t. and the precipitate was collected by filtration. The solids were washed with toluene, air dried then added to a mixture of 50mL 1N aq. NaOH and 100mL EtOAc. The solids were filtered and washed with EtOAc. The filtrate was transferred to a separatory funnel and the layers separated. The aqueous layer was extracted with excess EtOAc. The organic layers were combined and the solvent removed under vacuum to afford the product as a yellow solid, MS: *m/z* 259 (MH^+).

Step D: Preparation of *N*-(4-amino-2-propylquinolin-6-yl)acetamide

An intimate mixture of the crude product (4.0g) from Step C and ammonium acetate (40g, 52mmol) were heated at 140° to 150° for 4h. The reaction mixture was cooled to r.t. to provide the crude product which used immediately without further purification.

Step E: Preparation of 2-propylquinoline-4,6-diamine

To the above crude reaction mixture from Step D was added 30mL water and 40mL conc. HCl. The resulting mixture was heated at 90° for 5h then cooled to r.t. The

remaining precipitate was collected by filtration. The aqueous filtrate was concentrated under vacuum then made basic by addition of aq. sodium hydroxide. The aqueous mixture was transferred to a separatory funnel and extracted with excess EtOAc. The organic layers were combined, dried with a drying agent and the solvent removed under vacuum to afford a solid, MS: *m/z* 202 (MH^+).

Step F: Preparation of (2*E*)-3-(4-chlorophenyl)prop-2-enoyl chloride

To a solution of (2*E*)-3-(4-chlorophenyl)prop-2-enoic acid (2.0g, 11mmol) in 50mL methylene chloride was added oxalyl chloride (1.05mL, 12.1mmol) and N,N-dimethylformamide (0.05mL, 0.6mmol). The resulting mixture was stirred at r.t. for 6h. The solvent was removed under vacuum. The resulting solid was diluted with hexanes and the solvent removed under vacuum to provide an off-white solid, which was used without further purification.

Step G Preparation of (2*E*)-*N*-(4-Amino-2-propylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide

To a solution of the product of Step E (60mg, 0.3mmol) in 1.5mL HOAc was added the product of Step F (64mg, 0.32mmol). The resulting mixture was stirred at r.t. for 6h then the solvent removed under vacuum. The residue was purified by preparative TLC eluting with chloroform/ 2N ammonia in methanol (9/1) to afford the product, MS: *m/z* 366 (MH^+).

Following a procedure similar to that described above for Example 1, the following compounds were prepared from 2-propylquinoline-4,6-diamine (Example 1, Step E):



Ex. #	R_7	Parent Ion (MH^+) *m/z*
2		406

3		332
4		334
5		346
6		366
7		345
8		350
9		322
10		400
11		377
12		400
13		400
14		392
15		408
16		377
17		377

18		412
19		400
20		346
21		368
22		388
23		306
24		382
25		388
26		402
27		434
28		378
29		406
30		374
31		388
32		378
33		450

34		372
35		404
36		348
37		438
38		407
39		458
40		356
41		356
42		388
43		360
44		374
45		382
46		382
47		374

48		388
49		425
50		396
51		370
52		398
53		496
54		422
55		416
56		347
57		410
58		390
59		348
60		382
61		432
62		382
63		401

64	 isomer A	380
65	 isomer B	380
66		338
67		340
68		366
69		368
70		408
71		350
72		366
73		566
74		408
75		414

76		346
77		493
78		493

Following procedures similar to those described above for Example 1, the following compounds were prepared from the appropriate starting materials.



Ex. #	R_7	R_4	Parent Ion (MH+) *m/z*
79			339
80			305
81			304
82			328
83			372
84			372

85			400
86			400
87			366
88			400
89			386
90			414
91			352
92			380
93			338
94			402
95			368
96			366
97			400
98			384
99			418
100			334

101			402
102			368
103			380
104			414
105			380
106			414
107			416
108			382
109			394
110			428
111			394
112			396
113			430
114	 (isomer A)		408

115	 (isomer B)		408
116			472
117			378
118			392
119			406
120			412
121			426
122			440
123			346

EXAMPLE 124



(2*E*)-*N*-(4-amino-2-pentylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide

Step A: Preparation of methyl (2*E*)-3-{[4-(acetylamino)phenyl]amino}oct-2-enoate

A mixture of N-(4-aminophenyl)acetamide (8.9g, 59mmol), methyl oct-2-ynoate (10g, 64.8mmol), anhydrous potassium fluoride (1g, 17mmol) in 100mL anhydrous

N,N-dimethylformamide was purged with nitrogen then heated at 50° overnight. After approximately 18 h, the reaction mixture was cooled to r.t., and filtered. The filtrate was added to 100mL water, transferred to a separatory funnel and extracted with diethyl ether (5x100mL). The ether extracts were combined, dried over sodium sulfate, filtered and the solvent removed under vacuum. The resulting dark oil was purified by column chromatography on silica gel eluting with ethyl acetate/hexane gradient (1:2 to 100:0) to afford the product as a brown solid.

Step B: Preparation of *N*-(4-hydroxy-2-pentylquinolin-6-yl)acetamide

The product (2.0g) from Step A was mixed with 20mL of diphenylether. The mixture was heated with a heating mantle at 260° for 0.25h then cooled to r.t. The reaction mixture was diluted with EtOAc (25mL) and the resulting solid was collected by filtration, washed with EtOAc to give a brown solid, MS: *m/z* 273 (MH^+), which was used directly in the next step.

Step C: Preparation of *N*-(4-methoxy-2-pentylquinolin-6-yl)acetamide

The crude product (0.9g) from Step B and dimethylsulfate (0.4mL, 4mmol) were mixed in toluene (50mL) and heated at 60° for 4h. The reaction mixture was cooled to r.t., and the solvent removed under vacuum. The residue was purified by preparative thin layer chromatography eluting with EtOAc/hexanes (1:1) to afford the product as a brown solid, MS: *m/z* 287 (MH^+).

Step D: Preparation of *N*-(4-amino-2-pentylquinolin-6-yl)acetamide

An intimate mixture of the crude product (0.45g) from Step C and ammonium acetate (0.6g, 52mmol) were heated at 135° for 4h. The reaction mixture was cooled to r.t. and partitioned between 15mL 2N aq. NaOH and 15mL EtOAc. The aqueous layer was extracted with EtOAc (2X10mL). The organic extracts were combined, dried over sodium sulfate, filtered, and the solvent removed under vacuum. The residue was purified by preparative thin layer chromatography eluting with CH_2Cl_2/MeOH (9:1) to provide the product as a brown semi-solid, MS: *m/z* 272 (MH^+).

Step E: Preparation of 2-pentylquinoline-4,6-diamine

The product (225mg) from Step D was combined with 3mL conc. HCl, heated at 90° for 0.5h, and then cooled to r.t. The mixture was concentrated under vacuum then partitioned between 2N aq. sodium hydroxide (5mL) and EtOAc. The aqueous

mixture was transferred to a separatory funnel and extracted with excess EtOAc. The organic layers were combined, dried with a drying agent and the solvent removed under vacuum. The residue was purified by preparative thin layer chromatography eluting with CH_2Cl_2/MeOH (9:1) to afford the product as a brown semi-solid, MS: *m/z* 230 (MH^+).

Step F: Preparation of (2*E*)-*N*-(4-Amino-2-pentylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide

The product was prepared from the product of Step E (25mg, 0.3mmol) and (2*E*)-3-(4-chlorophenyl)prop-2-enoyl chloride (Example 1, Step F, 33mg, 0.16mmol) according to the procedure for Example 1, Step G. The product was obtained as an amber solid, MS: *m/z* 394 (MH^+).

Following procedures similar to those described above for Example 124, the following compounds were prepared from the appropriate starting materials:



Ex#	R_7	R_4	Parent Ion (MH^+) *m/z*
125			428
126			442
127			408

EXAMPLE 128



(2*E*)-*N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide

Step A: Preparation of ethyl (2*E*)-3-[(4-nitrophenyl)amino]hex-2-enoate

A mixture of 4-nitroaniline (15g, 109mmol), ethyl 3-oxohexanoate (10g, 95mmol) and p-toluenesulfonic acid (0.5g, 2.6mmol) toluene was heated at reflux in a flask equipped with a Dean-Stark apparatus and cooling condenser. After the theoretical amount of water was collected, the solvent was removed under vacuum. The residue was used without further purification in the subsequent reaction.

Step B: Preparation of 6-nitro-2-propylquinolin-4-ol

The crude product from Step A was mixed with diphenylether and the resulting mixture was heated with a heating mantle at 250° for 0.5h then cooled to r.t. The resulting solid was collected by filtration, washed with EtOAc to give a solid, which was used directly in the next step.

Step C: Preparation of 4-chloro-6-nitro-2-propylquinoline

The crude product (2.3g) from Step B and phosphorous oxychloride (10mL) were heated at 80° for 0.5h. The reaction mixture was cooled to r.t., poured carefully onto ice with shaking to decompose the excess $POCl_3$. The mixture was made basic by addition of 5N aq. NaOH. The aqueous layer was extracted with excess EtOAc, the organic layers were combined, dried, filtered and the solvent removed under vacuum to afford the product as a solid, MS: *m/z* 251 (MH^+).

Step D: Preparation of 4-azetidin-1-yl-6-nitro-2-propylquinoline

A mixture of the crude product (0.2g) from Step C and azetidine (0.25g, 52mmol) in methanol was heated at 80° in a sealed tube overnight. The reaction mixture was cooled to r.t. and the solvent removed under vacuum. The residue was purified by column chromatography eluting with EtOAc/hexanes (1:3) to provide the product, MS: *m/z* 272 (MH^+).

Step E: Preparation of 4-azetidin-1-yl-2-propylquinolin-6-amine

The product (170mg) from Step D was combined with $FeCl_3 \cdot 6H_2O$ (catalytic amount), carbon (110mg) in methanol. The mixture was heated at 70° for 0.25h then hydrazine (0.25mL) was added. The mixture was heated at reflux for 2.5h, cooled to r.t., and the solids filtered. The filtrate was concentrated under vacuum, then treated with 6N aq.

sodium hydroxide and methanol. The methanol was removed under vacuum. The aqueous mixture was transferred to a separatory funnel and extracted with excess EtOAc. The organic layers were combined, dried with a drying agent, and the solvent removed under vacuum to afford the product, MS: *m/z* 242 (MH^+).

Step F: Preparation of (2*E*)-3-[(4-trifluoromethyl)phenyl]prop-2-enoyl chloride

The product was prepared from (2*E*)-3-[(4-trifluoromethyl)phenyl]prop-2-enoic acid according to the procedure for Example 1, Step F.

Step G: Preparation of (2*E*)-*N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl) phenyl]prop-2-enamide

The product was prepared from the product of Step E (15mg) and (2*E*)-3-[(4-trifluoromethyl)phenyl]prop-2-enoyl chloride (Step F, 20mg) according to the procedure for Example 1, Step G. The product was obtained as a solid, MS: *m/z* 440 (MH^+).

Following procedures similar to those described above for Example 128, the following compounds were prepared from the appropriate starting materials:



Ex.#	R_7	$R = -NR_1R_2$	Parent Ion *m/z*
129			442
130			408
131			406
132			442
133			456

134	 isomer A		420
135	 isomer A		420
136			518
137			450
138			549
139			449
140			563

141			463
142			430
143			428
144			564
145			414
146			454
147			456
148			468
149			454
150			464
151			456
152			440
153			408
154			394
155			406

EXAMPLE 156



Ethyl 4-amino-2-propyl-6-({(2*E*)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl}amino)quinoline-3-carboxylate

Step A: Ethyl 4-amino-6-nitro-2-propylquinoline-3-carboxylate

To a stirred solution of ethyl 3-oxohexanoate (3.2mL, 20mmol) in toluene under nitrogen atmosphere was added 2-amino-5-nitrobenzonitrile (2.4g, 14.5mmol) followed by tin(IV) chloride (4.6mL, 39mmol). The resulting mixture was stirred at r.t. for 0.5h then heated at reflux for 3h. The reaction mixture was cooled to r.t., and the solvent removed under vacuum. To the residue was added saturated aq. sodium carbonate. The mixture was stirred until decomposition of the tin(IV) chloride was complete. The mixture was transferred to a separatory funnel and extracted with excess EtOAc. The extracts were combined, dried over a drying agent, filtered and the solvent removed under vacuum. The residue was passed through a pad of silica gel eluting with EtOAc to provide the product as a yellow solid, which was used in the next step.

Step B: Ethyl 4,6-diamino-2-propylquinoline-3-carboxylate

The product was prepared from ethyl 4-amino-6-nitro-2-propylquinoline-3-carboxylate (Step A) according to the procedure for Example 128, Step E, MS: *m/z* 274 (MH^+).

Step C: Ethyl 4-amino-2-propyl-6-({(2*E*)-3-[4-(trifluoromethyl)phenyl]prop-2-enoyl}amino)quinoline-3-carboxylate

The product was prepared from ethyl 4,6-diamino-2-propylquinoline-3-carboxylate (Step B) and (2*E*)-3-[(4-trifluoromethyl)phenyl]prop-2-enoyl chloride (Example 128, Step F) according to the procedure for Example 1, Step G, MS: *m/z* 472 (MH^+).

Following procedures similar to those described above for Example 156, the following compounds were prepared from the appropriate starting materials or by functional group manipulation of intermediates or products here-in or above.

Ex.#	Structure	Parent Ion (MH+) m/z
157		412
158		440
159		396
160		430
161		432
162		444
163		412
164		392
165		378

166		394

EXAMPLE 167



4-Amino-*N*-[4-(trifluoromethyl)benzyl]-2-propylquinoline-6-carboxamide

Step A: Ethyl 4-{[(1*E*)-3-ethoxy-3-oxo-1-propylprop-1-enyl]amino}benzoate

The product was prepared from ethyl 4-aminobenzoate and ethyl 3-oxohexanoate according to the procedure for Example 1, Step A.

Step B: Ethyl 4-hydroxy-2-propylquinoline-6-carboxylate

The product was prepared from ethyl 4-{[(1*E*)-3-ethoxy-3-oxo-1-propylprop-1-enyl]amino}benzoate (Step A) according to the procedure for Example 1, Step B.

Step C: Ethyl 4-methoxy-2-propylquinoline-6-carboxylate

The product was prepared from ethyl 4-hydroxy-2-propylquinoline-6-carboxylate (Step B) according to the procedure for Example 1, Step C.

Step D: 4-Methoxy-2-propylquinoline-6-carboxylic acid

A mixture of ethyl 4-methoxy-2-propylquinoline-6-carboxylate (Step C), KOH (15mg) in 0.5mL water and 5mL ethanol was heated at reflux for 3h. The mixture was cooled to r.t., diluted with water, acidified with aq. HCl and extracted with excess EtOAc. The extracts were combined, dried and solvent removed under vacuum to provide the product which was used in the next Step without further purification.

Step F: 4-Methoxy-2-propyl-*N*-[4-(trifluoromethyl)benzyl]quinoline-6-carboxamide

To a solution of 4-methoxy-2-propylquinoline-6-carboxylic acid (Step D, 18mg, 0.07mmol) in anhydrous methylene chloride (3mL) and anhydrous *N,N*-dimethylformamide (1.5mL) was added EDC (1.5 eq.), HOBT (1.0 eq.) and 4-(trifluoromethyl)benzylamine (30mg, 2.3 eq.). The reaction mixture was stirred at r.t.

for 3 days. The mixture was quenched with water and extracted with excess EtOAc. The combined extracts were dried over a drying agent filtered and the solvent removed under vacuum. The residue was purified by preparative TLC eluting with EtOAc to afford the the product.

Step G: 4-Amino-*N*-[4-(trifluoromethyl)benzyl]-2-propylquinoline-6-carboxamide

The product, MS: *m/z* 388, was prepared from 4-methoxy-2-propyl-*N*-[4-(trifluoromethyl)benzyl]quinoline-6-carboxamide (Step F) according to the procedure for Example 1, Step G.

Using procedures analogous to those described above the following Examples were prepared from the appropriate starting materials.



Ex.#	R_6	Parent Ion (MH+) *m/z*
168		402
169		368
170		416
171		374
172		416

173		416
174		402
175		388

EXAMPLE 176



2-Propyl-6-{5-[4-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}quinolin-4-amine

Step A: Ethyl (2*E*)-3-[(4-cyanophenyl)amino]hex-2-enoate

The product was prepared from 4-aminobenzonitrile and ethyl 3-oxohexanoate according to the procedure for Example 1, Step A.

Step B: 4-Hydroxy-2-propylquinoline-6-carbonitrile

The product was prepared from ethyl (2*E*)-3-[(4-cyanophenyl)amino]hex-2-enoate (Step A) according to the procedure for Example 1, Step B.

Step C: 4-Methoxy-2-propylquinoline-6-carbonitrile

The product MS: *m/z* 227, was prepared from 4-hydroxy-2-propylquinoline-6-carbonitrile (Step B) according to the procedure for Example 1, Step C.

Step D: *N'*-hydroxy-4-methoxy-2-propylquinoline-6-carboximidamide

Or *N*-hydroxy-4-methoxy-2-propylquinoline-6-carboximidamide

A mixture of 4-methoxy-2-propylquinoline-6-carbonitrile (Step C, 900mg), hydroxylamine hydrochloride (3 eq.), sodium carbonate (3 eq.) in 3mL water and 10mL ethanol was stirred overnight. The mixture was diluted with water,

extracted with excess EtOAc. The extracts were combined, dried and solvent removed under vacuum. The residue was triturated with EtOAc and the solvent decanted away to provide the product (610mg)which was used in the next step without further purification.

Step E: 4-Methoxy-6-{5-[4-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}-2-propylquinoline

To a mixture of the product of Step D, (130mg) in anhydrous diglyme (10mL) was added 4-trifluoromethylphenylacetic acid (2 eq.), EDC (2 eq.) and HOBT (1.0 eq.). The reaction mixture was stirred at r.t. overnight. After approximately 18hr, the mixture was heated at 130 for 2hr. The mixture was cooled to r.t., quenched with water and extracted with excess EtOAc. The combined extracts were dried over a drying agent filtered and the solvent removed under vacuum. The residue was purified by preparative TLC eluting with EtOAc to afford the product (115mg).

Step F: 2-Propyl-6-{5-[4-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}quinolin-4-amine

The product (58mg), MS: *m/z* 413, was prepared from 4-methoxy-6-{5-[4-(trifluoromethyl)benzyl]-1,2,4-oxadiazol-3-yl}-2-propylquinoline (70mg, Step E) according to the procedure for Example 1, Step D,

Using procedures analogous to those described above the following Examples were prepared from the appropriate starting materials:



Ex.#	R_6	Parent Ion (MH^+) *m/z*
177		399

178		399
179		377
180		393
181		413
182		427
183		427
184		441
185		425
186		391
187		393
188		407

189		407
190		501
191		421

EXAMPLE 192



2-Propyl-N^6-{3-[4-(trifluoromethyl)phenyl]propyl}quinoline-4,6-diamine

Step A: 2-Propyl-N^6-{3-[4-(trifluoromethyl)phenyl]propyl}quinoline-4,6-diamine

To a solution of *N*-(4-amino-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl] propanamide (86mg, 0.2mmol, Example 26) in 6mL THF under nitrogen atmosphere was added lithium aluminium hydride (400mg, 10.5mmol). The reaction mixture was heated at reflux for 3h, then cooled in an ice bath. The reaction was quenched by careful addition of water (1mL) followed by 5N aq. potassium hydroxide (1mL). The viscous mixture was triturated with excess EtOAc and the solvents decanted away. This was repeated three times. The organic layers were combined, dried over magnesium sulfate, filtered and the solvent removed under vacuum. The residue was purified by preparative TLC eluting with CHCL3/2N NH3 in MeOH (9:1) to afford the product as a tan solid, MS: *m/z* 388 (MH^+).

Using chemistry known to those skilled in the art, the following compounds were made using analogous procedures used to prepare Example 192 shown above or by functional group manipulation of intermediates and/or examples shown above.



Ex.#	R_6	Parent Ion (MH+) *m/z*
193		436
194A		388
194B		374
195		340
196		354
197		402
198		430
199		416
200		402

Using chemistry known to those skilled in the art, the following compounds were made using analogous procedures used to prepare the examples shown above or by functional group manipulation of intermediates and/or examples shown above.

Ex.#	Structure	Parent Ion (MH+) *m/z*
201		402
202		416
203		414
204		388
205		366
206		400

207		400
208		452

Example 209



N-(4-amino-2-propylquinolin-6-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea

To a solution of triphosgene (27mg, 0.09mmol) in methylene chloride (0.6mL) under nitrogen atmosphere was added a mixture of 4-trifluoromethylbenzylamine (0.04mL, 0.28mmol) and N,N-diisopropylethylamine (0.11mL) over 15minutes by syringe pump. The resulting mixture was stired at r.t. for 0.25h and the solvent removed under vacuum to provide a solid. The solid was added a solution of 2-propylquinoline-4,6-diamine (52mg, 0.26mmol; Example 1 Step E) in acetic acid (1.5mL). The reaction mixture was stirred at r.t. for 3.5h and the solvent removed under vacuum. The residue was purified by preparative TLC eluting with $CHCl_3$/2N NH_3 in MeOH (9:1) to afford the product as a solid, MS: *m/z* 403 (MH^+).

Using chemistry known to those skilled in the art, the following compounds were made using analogous procedures used to prepare the examples shown above or by functional group manipulation of intermediates and/or examples shown above.



Ex. #	R_6	R_4	Parent Ion (MH^+) *m/z*
210			389
211			355
212			397
213			417
214			349
215			327
216			335
217			397
218			371
219			405

220			367
221			413
222			351
223			493
224			349
225			389
226			403
227			371
228			441
229			469
230			403
231			417

232			403
233			471
234			429
235			404
236			504
237			404
238			504
239			490
240			390
241			486

242			504
243			389
244			407

BIOLOGICAL ASSAYS

MCH-1R and MCH-2R Radioligand Binding assays

Membrane binding assays were performed on transiently-transfected COS-7 cells expressing human MCH-2R from the plasmid vector pCI-neo (Promega, Madison, WI), on a Chinese hamster ovary (CHO) cell line stably expressing the MCH-2R from the plasmid vector pEF1/V5-HisB (Invitrogen, Carlsbad, CA), or a CHO cell line stably expressing human MCH-1R from pcDNA3.1. For transient expression, COS-7 cells were cultured in Dulbecco's modified Eagle medium (Gibco BRL, Rockville, MD) with 10 % heat inactivated fetal calf serum. A suspension of 7 x 10^6 COS-7 cells were transfected with 20 μg of pCI-neo/MCH-2R plasmid by electroporation *(26)* and cells were harvested after 60-72 hours. Membranes were prepared from transient and stable transfectants by hypotonic lysis, frozen in liquid nitrogen, and stored at – 80°C. A scintillation proximity assay (SPA) was developed to measure the specific binding of [^{125}I]-[Phe^{13}Tyr^{19}]-hMCH. SPA were carried out using wheat-germ agglutinin-polyvinyltoluene beads (Amersham Corp., Arlington Heights, IL), in 96-well OptiPlates (Packard, Meriden, CT). Each well contained 0.25 mg of SPA beads, 1-10 μg of membrane protein, and 200 μL binding buffer (50 mM Tris pH 7.4, 10 mM $MgCl_2$, 2 mM EDTA, 12% glycerol, 0.1% BSA). Binding buffer contained 50 mM Tris pH 7.4, 8 mM $MgCl_2$,, 12 % glycerol, 0.1 % BSA (Sigma, St. Louis, MO) and protease inhibitors: 4 μg/mL of leupeptin (Sigma, St. Louis, MO), 40 μg/mL of Bacitracin (Sigma, St. Louis, MO), 5 μg/mL of Aprotinin (Roche Molecular Biochem., Indianapolis, IN), 0.05M AEBSF (Roche Molecular Biochem., Indianapolis, IN), and 5 mM Phosphoramidon (Boeringer Mannheim). Assays were optimized with respect to membrane preparations: for CHO/MCH-1R membranes, 1 μg of membranes per well yielded a > 6x specific binding window and for COS or

CHO MCH-2R membranes, 8 μg of membrane protein yielded a window of about 3x. Specific binding is defined as the difference between total binding and non-specific binding conducted in the presence of 500 nM unlabeled hMCH. Beads were coated with membranes for 20 minutes and dispensed to the 96 wells, various concentrations of test compounds in DMSO were added (final DMSO concentration 1 % - 2 %), then 25 nCi of [^{125}I]-[Phe^{13}Tyr^{19}]-hMCH (~2000 Ci/mmol; NEN Life Sciences, Boston, MA) was added to the wells. After equilibrating at r.t. for 3 hours, the plates were read in a TopCount (Packard, Meriden, CT). IC_{50} calculations were performed using Prism 3.0 (GraphPad Software, San Diego, CA). The IC_{50} values were measured in three different experiments. A filter-based assay was also used for MCH-2R in 96-well plates. Total volume per binding assay point was 200 μL. Binding conditions were 50 mM Tris pH 7.4, 10 mM $MgCl_2$, 2 mM EDTA 200 μg/mL bacitracin, 1 μM phosphoramidon, 2.5 to 5 μg protein, with and without 10 μM MCH unlabeled peptide as a competitor. Dose response curves were from 10 μM in 5 fold or 3-fold dilution series for 11 points. The mixture was shaken for 5 minutes on a platform shaker, and incubated at r.t. for 1 hour. Filter plates were presoaked in 1% PEI. The binding reaction was harvested onto filters using Packard Filtermate harvester (Meriden, CT). The filters were then washed in 50 mM Tris pH 7.4, 10 mM $MgCl_2$, 2 mM EDTA, 0.04% Tween 20, 6-8 times per plate. The plates were dried for 20 minutes at 55 °C or overnight at r.t. 30 μL microscintillant was added per well and counted for 1.5-3 minutes in inverted format on Packard TopCount. IC_{50} calculations were performed using Prism 3.0 (GraphPad Software, San Diego, CA).

Functional Assay for MCH-1R and MCH-2R

The aequorin bioluminescence assay is a reliable test for identifying G-protein-coupled receptors which couple through the G protein subunit family consisting of G_q and G_{ii} which leads to the activation of phospholipase C, mobilization of intracellular calcium, and activation of protein kinase C. Stable cell lines expressing either the MCH-1R or the MCH-2R and the aequorin reporter protein were used. The assay was performed using a Luminoskan RT luminometer (Labsystems Inc., Gaithersburg, MD) controlled by custom software written for a Macintosh PowerPC 6100. 293AEQ17/MCH-1R(or MCH-2R) cells were cultured for 72 h and the apo-aequorin in the cells was charged for 1 h with coelenterazine (10 μM) under reducing conditions (300 M reduced glutathione) in ECB buffer (140 mM NaCl, 20 mM KCl, 20 mM HEPES-NaOH, pH 7.4, 5 mM glucose, 1 mM $MgCl_2$, 1 mM $CaCl_2$, 0.1

mg/mL bovine serum albumin). The cells were harvested, washed once in ECB medium, and resuspended to 500 000 cells/mL. 100 µL of cell suspension (corresponding to 5×10^4 cells) was then injected into the test plate containing the test ligands, and the integrated light emission was recorded over 30 s, in 0.5-s units. 20 µL of lysis buffer (0.1% final Triton X-100 concentration) was then injected and the integrated light emission recorded over 10 s, in 0.5-s units. To detect antagonists, test ligands were pre-incubated for ~10 minutes at varying concentrations prior to injection on the test ligand plate containing MCH agonists. The "fractional response" values for each well were calculated by taking the ratio of the integrated response to the initial challenge to the total integrated luminescence including the Triton X-100 lysis response. The functional EC_{50} values were measured in three separate assays.

Selective MCH-1R antagonist compounds of the present invention have IC_{50} affinities for the MCH-1R receptor between 0.1 and 10000 nM, are at least 20x selective for the MCH-1R receptor over the MCH-2R receptor, and are functional antagonists lacking agonist activity at the MCH-1R receptor.

References:

MCH-1R (human):

Lakaye et al., " Cloning of the rat brain cDNA encoding for the SLC-1 G protein-coupled receptor reveals the presence of an intron in the gene," Biochim. Biophys Acta; 1401(2):216-20 (1998).

Saito et al., "Molecular characterization of the melanin-concentrating-hormone receptor", Nature;.400(6741):265-9 (1999).

Chambers et al., "Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1", Nature; 400(6741):261-5 (1999).

MCH-2R (human):

Sailer et al., "Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R", Proc. Natl. Acad. Sci. U S A; 98(13):7564-9 (2001).

In vivo food intake models.

1) Overnight food intake. Sprague Dawley rats are injected intracerebroventricularly with a test compound in 400 nL of 50% propylene glycol/artificial cerebrospinal fluid one hour prior to onset of dark cycle (12 hours). Food intake is determined using a computerized system in which each rat's food is placed on a computer monitored balance. Cumulative food intake for 16 hours post compound administration is measured.

2) Food intake in diet induced obese mice. Male C57/B16J mice maintained on a high fat diet (60% fat calories) for 6.5 months from 4 weeks of age are dosed intraperitoneally with test compound. Food intake and body weight are measured over an eight day period. Biochemical parameters relating to obesity, including leptin, insulin, triglyceride, free fatty acid, cholesterol and serum glucose levels are determined.

While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses as set forth hereinabove may be applicable as a consequence of variations in the responsiveness of the mammal being treated for obesity, diabetes, or for other indications for the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims that follow and that such claims be interpreted as broadly as is reasonable.

WHAT IS CLAIMED IS:

1. A compound of structural formula (I):



(I)

wherein:

R^1 and R^2 are independently selected from the group consisting of:

(1) hydrogen,

(2) C_{1-6} alkyl,

(3) C_{2-6} alkenyl,

(4) C_{2-6} alkynyl,

(5) cycloalkyl-C_{0-6} alkyl,

(6) heterocycloalkyl-C_{0-10} alkyl,

(7) aryl-C_{0-10} alkyl, and

(8) heteroaryl-C_{0-10} alkyl;

wherein alkyl, alkenyl, and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

or, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, optionally containing one or two additional heteroatoms selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

R^3 and R^4 are independently selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) perfluoro C_{1-6} alkyl,
(5) C_{2-6} alkenyl,
(6) C_{2-6} alkynyl,
(7) cycloalkyl,
(8) cycloalkyl-C_{1-6} alkyl,
(9) cycloheteroalkyl,
(10) cycloheteroalkyl-C_{1-6} alkyl,
(11) aryl,
(12) aryl-C_{1-6} alkyl,
(13) heteroaryl,
(14) heteroaryl-C_{1-6} alkyl,
(15) $-OR^7$,
(16) $-NR^7R^7$,
(17) $-CO_2R^7$,
(18) cyano, and
(19) $-C(O)NR^7R^7$;

wherein alkyl, alkenyl and alkynyl, moieties above are optionally substituted with one to four substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to four substituents independently selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;
or, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered heterocycloalkyl or cycloalkyl ring, either unsubstituted or substituted with one to four substituents independently selected from R^b;

R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) C_{1-6} alkyl,
(4) perfluoro C_{1-6} alkyl,

(5) $-OR^7$, and
(6) $-NR^7R^7$;

R^6 is selected from the group consisting of:
(1) $-(CH_2)_n-R^7$,
(2) $-(CH_2)_n$-aryl-R^7,
(3) $-(CH_2)_n$-heteroaryl-R^7,
(4) $-(CH_2)_n$-heterocycloalkyl-R^7,
(5) $-(CH_2)_nC{\equiv}N$,
(6) $-(CH_2)_nCON(R^7)_2$,
(7) $-(CH_2)_nCO_2R^7$,
(8) $-(CH_2)_nCOR^7$,
(9) $-(CH_2)_nNR^7C(O)R^7$,
(10) $-(CH_2)_nNR^7C(O)(CH_2)_nSR^7$
(11) $-(CH_2)_nNR^7CO_2R^7$,
(12) $-(CH_2)_nNR^7C(O)N(R^7)_2$,
(13) $-(CH_2)_nNR^7SO_2R^7$,
(14) $-(CH_2)_nS(O)_pR^7$,
(15) $-(CH_2)_nSO_2N(R^7)_2$,
(16) $-(CH_2)_nOR^7$,
(17) $-(CH_2)_nOC(O)R^7$,
(18) $-(CH_2)_nOC(O)OR^7$,
(19) $-(CH_2)_nOC(O)N(R^7)_2$,
(20) $-(CH_2)_nN(R^7)_2$, and
(21) $-(CH_2)_nNR^7SO_2N(R^7)_2$,
wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a;

R^7 is independently selected at each occurrence from the group consisting of:
(1) hydrogen,
(2) C_{1-6} alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,

(7) aryl C_{1-3} alkyl,
(8) heteroaryl C_{1-3} alkyl,
(9) cycloalkyl C_{1-3} alkyl,
(10) heterocycloalkyl C_{1-3} alkyl,
(11) aryl C_{2-3} alkenyl,
(12) heteroaryl C_{2-3} alkenyl,
(13) cycloalkyl C_{2-3} alkenyl, and
(14) heterocycloalkyl C_{2-3} alkenyl,

wherein the alkyl and alkenyl moieties are optionally substituted with one to four substituents selected from R^a; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to four substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

each R^a is independently selected from:

(1) $-OR^d$,
(2) $-NR^dS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^d$,
(6) $-SR^d$,
(7) $-S(O)_2OR^d$,
(8) $-S(O)_pN(R^d)_2$,
(9) $-N(R^d)_2$,
(10) $-O(CR^dR^d)_nN(R^d)_2$,
(11) $-C(O)R^d$,
(12) $-CO_2R^d$,
(13) $-CO_2(CR^dR^d)_nCON(R^d)_2$,
(14) $-OC(O)R^d$,
(15) -CN,
(16) $-C(O)N(R^d)_2$,
(17) $-NR^dC(O)R^d$,
(18) $-OC(O)N(R^d)_2$,
(19) $-NR^dC(O)OR^d$,
(20) $-NR^dC(O)N(R^d)_2$,

(21) $-CR^d(N-OR^d)$,
(22) $-CF_3$,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;

each R^b is independently selected from:
(1) R^a,
(2) $-Sn(CH_3)_3$,
(3) C_{1-10} alkyl,
(4) C_{2-10} alkenyl,
(5) C_{2-10} alkynyl,
(6) heteroaryl,
(7) aryl, and
(8) aryl-C_{1-10} alkyl;
wherein alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl are optionally substituted with one to four substituents selected from a group independently selected from R^c;

each R^c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C_{1-4} alkyl,
(5) C_{1-4} alkoxy,
(6) aryl,
(7) aryl C_{1-4} alkyl,
(8) hydroxy,
(9) $-CF_3$,
(10) $-OC(O)C_{1-4}$ alkyl,
(11) $-OC(O)N(R^d)_2$, and
(12) aryloxy;

R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl; C_{2-6} alkynyl; cycloalkyl; cycloalkyl-C_{1-6} alkyl; cycloheteroalkyl; cycloheteroalkyl-C_{1-6} alkyl; aryl; heteroaryl; aryl-C_{1-6} alkyl; and heteroaryl-C_{1-6} alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to four substituents independently selected from R^e;
each R^e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;

m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, 4, and 5;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.

2. The compound according to Claim 1, wherein:
R^1 and R^2 are independently selected from the group consisting of:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) C_{2-6} alkenyl,
(4) cycloalkyl-C_{0-6} alkyl,
(5) heterocycloalkyl-C_{0-6} alkyl,
(6) aryl-C_{0-6} alkyl, and
(7) heteroaryl-C_{0-10} alkyl;

wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b;

or, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, optionally having one or more degrees of unsaturation, optionally fused to a 6-membered heteroaromatic or aromatic ring, either unsubstituted or substituted with an R^b substituent;

R^3 and R^4 are independently selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) C_{2-6} alkenyl,
(6) cycloalkyl,
(7) cycloalkyl-C_{1-6} alkyl,
(8) cycloheteroalkyl,
(9) cycloheteroalkyl-C_{1-6} alkyl,
(10) aryl,
(11) aryl-C_{1-6} alkyl,.
(12) heteroaryl,
(13) heteroaryl-C_{1-6} alkyl,
(14) $-OR^7$,
(15) $-NR^7R^7$,
(16) $-CO_2R^7$, and
(17) $-C(O)NR^7R^7$;

wherein alkyl and alkenyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent;

or, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered heterocycloalkyl or cycloalkyl ring, either unsubstituted or substituted with an R^b substituent;

R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) methyl,
(4) trifluoromethyl,
(5) hydroxy,
(6) methoxy,
(7) phenoxy,

(8) $-NH_2$,
(9) $-NH(CH_3)$, and
(10) $-N(CH_3)_2$;

R^6 is selected from the group consisting of :
(1) $-(CH_2)_n-R^7$,
(2) $-(CH_2)_n$-aryl-R^7,
(3) $-(CH_2)_n$-heteroaryl-R^7,
(4) $-(CH_2)_n$-heterocycloalkyl-R^7,
(5) $-(CH_2)_nC\equiv N$,
(6) $-(CH_2)_nCON(R^7)_2$,
(7) $-(CH_2)_nCO_2R^7$,
(8) $-(CH_2)_nCOR^7$,
(9) $-(CH_2)_nNR^7C(O)R^7$,
(10) $-(CH_2)_nNR^7C(O)(CH_2)_nSR^7$
(11) $-(CH_2)_nNR^7CO_2R^7$,
(12) $-(CH_2)_nNR^7C(O)N(R^7)_2$,
(13) $-(CH_2)_nNR^7SO_2R^7$,
(14) $-(CH_2)_nS(O)_pR^7$,
(15) $-(CH_2)_nSO_2N(R^7)_2$,
(16) $-(CH_2)_nOR^7$,
(17) $-(CH_2)_nOC(O)R^7$,
(18) $-(CH_2)_nOC(O)OR^7$,
(19) $-(CH_2)_nOC(O)N(R^7)_2$,
(20) $-(CH_2)_nN(R^7)_2$, and
(21) $-(CH_2)_nNR^7SO_2N(R^7)_2$,
wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a;

R^7 is independently selected at each occurrence from the group consisting of
(1) hydrogen,
(2) C_{1-6} alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,

(6) heterocycloalkyl,
(7) aryl C_{1-3} alkyl,
(8) heteroaryl C_{1-3} alkyl,
(9) cycloalkyl C_{1-3} alkyl,
(10) heterocycloalkyl C_{1-3} alkyl,
(11) aryl C_{2-3} alkenyl,
(12) heteroaryl C_{2-3} alkenyl,
(13) cycloalkyl C_{2-3} alkenyl, and
(14) heterocycloalkyl-C_{2-3} alkenyl,

wherein the alkyl and alkenyl moieties are optionally substituted with one to four substituents selected from R^a; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to four substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

each R^a is independently selected from:

(1) $-OR^d$,
(2) $-NR^dS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^d$,
(6) $-SR^d$,
(7) $-S(O)_2OR^d$,
(8) $-S(O)_pN(R^d)_2$,
(9) $-N(R^d)_2$,
(10) $-O(CR^dR^d)_nN(R^d)_2$,
(11) $-C(O)R^d$,
(12) $-CO_2R^d$,
(13) $-CO_2(CR^dR^d)_nCON(R^d)_2$,
(14) $-OC(O)R^d$,
(15) -CN,
(16) $-C(O)N(R^d)_2$,
(17) $-NR^dC(O)R^d$,
(18) $-OC(O)N(R^d)_2$,
(19) $-NR^dC(O)OR^d$,
(20) $-NR^dC(O)N(R^d)_2$,

(21) -$CR^d(N\text{-}OR^d)$,

(22) -CF_3,

(23) cycloalkyl,

(24) cycloheteroalkyl, and

(25) oxo;

each R^b is independently selected from:

(1) R^a,

(2) -$Sn(CH_3)_3$,

(3) $C_{1\text{-}10}$ alkyl,

(4) $C_{2\text{-}10}$ alkenyl,

(5) heteroaryl,

(6) aryl, and

(7) aryl-$C_{1\text{-}10}$ alkyl;

wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl are optionally substituted with one to four substituents selected from a group independently selected from R^c;

each R^c is independently selected from:

(1) halogen,

(2) amino,

(3) carboxy,

(4) $C_{1\text{-}4}$ alkyl,

(5) $C_{1\text{-}4}$ alkoxy,

(6) aryl,

(7) aryl $C_{1\text{-}4}$ alkyl-,

(8) hydroxy,

(9) -CF_3,

(10) -$OC(O)C_{1\text{-}4}$ alkyl,

(11) -$OC(O)N(R^d)_2$, and

(12) aryloxy;

R^d is independently selected from hydrogen, $C_{1\text{-}6}$ alkyl, $C_{2\text{-}6}$ alkenyl; $C_{2\text{-}6}$ alkynyl; cycloalkyl; cycloalkyl-$C_{1\text{-}6}$ alkyl; cycloheteroalkyl; cycloheteroalkyl-$C_{1\text{-}6}$ alkyl; aryl; heteroaryl; aryl-$C_{1\text{-}6}$ alkyl; and heteroaryl-$C_{1\text{-}6}$ alkyl;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to two substituents independently selected from a R^e;
each R^e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;
m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, 4, and 5;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.

3. The compound according to Claim 2, wherein:

R^1 is selected from the group consisting of:

(1) hydrogen, and
(2) C_{1-6} alkyl, optionally substituted with one to three substituents independently selected from R^a;

R^2 is selected from the group consisting of:

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) cycloalkyl-C_{0-6} alkyl,
(4) heterocycloalkyl-C_{0-6} alkyl,
(5) aryl-C_{0-6} alkyl, and
(6) heteroaryl-C_{0-10} alkyl;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b;

or, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O , either unsubstituted or substituted with an R^b substituent;

R^3 is selected from the group consisting of:

(1) hydrogen,
(2) halogen,

(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) –OH,
(6) $–OCH_3$,
(7) $–NH_2$,
(8) $-CO_2R^7$, and
(9) $–C(O)NH_2$;

wherein alkyl moieties above are optionally substituted with one to two substituents independently selected from R^a;

R^4 is selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) cycloalkyl,
(6) cycloheteroalkyl,
(7) aryl,
(8) aryl-C_{1-6} alkyl,
(9) heteroaryl,
(10) –OH,
(11) –OCH,
(12) $–NH_2$,
(13) $-CO_2R^7$, and
(14) $–C(O)NH_2$;

wherein alkyl moieties above are optionally substituted with one to four substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent;

or, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered cycloalkyl ring, either unsubstituted or substituted with an R^b substituent;

R^5 is selected from:

(1) hydrogen,
(2) halogen,
(3) methyl,
(4) trifluoromethyl,
(5) hydroxy,
(6) methoxy,
(7) phenoxy,
(8) $-NH_2$,
(9) $-NH(CH_3)$, and
(10) $-N(CH_3)_2$;

R^6 is selected from the group consisting of :
(1) $-(CH_2)_n-R^7$,
(2) $-(CH_2)_n$-aryl-R^7,
(3) $-(CH_2)_n$-heteroaryl-R^7,
(4) $-(CH_2)_n$-heterocycloalkyl-R^7,
(5) $-(CH_2)_nC{\equiv}N$,
(6) $-(CH_2)_nCON(R^7)_2$,
(7) $-(CH_2)_nCO_2R^7$,
(8) $-(CH_2)_nCOR^7$,
(9) $-(CH_2)_nNR^7C(O)R^7$,
(10) $-(CH_2)_nNR^7C(O)(CH_2)_nSR^7$
(11) $-(CH_2)_nNR^7CO_2R^7$,
(12) $-(CH_2)_nNR^7C(O)N(R^7)_2$,
(13) $-(CH_2)_nNR^7SO_2R^7$,
(14) $-(CH_2)_nS(O)_pR^7$,
(15) $-(CH_2)_nSO_2N(R^7)_2$,
(16) $-(CH_2)_nOR^7$,
(17) $-(CH_2)_nOC(O)R^7$,
(18) $-(CH_2)_nOC(O)OR^7$,
(19) $-(CH_2)_nOC(O)N(R^7)_2$,
(20) $-(CH_2)_nN(R^7)_2$, and
(21) $-(CH_2)_nNR^7SO_2N(R^7)_2$,

wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a;

R^7 is independently selected at each occurrence from the group consisting of

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C_{1-3} alkyl,
(8) heteroaryl C_{1-3} alkyl,
(9) cycloalkyl C_{1-3} alkyl,
(10) heterocycloalkyl C_{1-3} alkyl,
(11) aryl C_{2-3} alkenyl,
(12) heteroaryl C_{2-3} alkenyl,
(13) cycloalkyl C_{2-3} alkenyl, and
(14) heterocycloalkyl C_{2-3} alkenyl,

wherein the alkyl and alkenyl moieties are optionally substituted with one to three substituents selected from R^a; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

each R^a is independently selected from:

(1) $-OR^d$,
(2) $-NR^dS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^d$,
(6) $-SR^d$,
(7) $-S(O)_2OR^d$,
(8) $-S(O)_pN(R^d)_2$,
(9) $-N(R^d)_2$,
(10) $-O(CR^dR^d)_nN(R^d)_2$,
(11) $-C(O)R^d$,

(12) $-CO_2R^d$,
(13) $-CO_2(CR^dR^d)_nCON(R^d)_2$,
(14) $-OC(O)R^d$,
(15) -CN,
(16) $-C(O)N(R^d)_2$,
(17) $-NR^dC(O)R^d$,
(18) $-OC(O)N(R^d)_2$,
(19) $-NR^dC(O)OR^d$,
(20) $-NR^dC(O)N(R^d)_2$,
(21) $-CR^d(N\text{-}OR^d)$,
(22) $-CF_3$,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;

each R^b is independently selected from:
(1) R^a,
(2) $-Sn(CH_3)_3$,
(3) $C_{1\text{-}10}$ alkyl,
(4) $C_{2\text{-}10}$ alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-$C_{1\text{-}10}$ alkyl;

wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R^a and R^b are optionally substituted with one to four substituents selected from a group independently selected from R^c;

each R^c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) $C_{1\text{-}4}$ alkyl,
(5) $C_{1\text{-}4}$ alkoxy,
(6) aryl,

(7) aryl C_{1-4} alkyl-,
(8) hydroxy,
(9) $-CF_3$,
(10) $-OC(O)C_{1-4}$ alkyl,
(11) $-OC(O)N(R^d)_2$, and
(12) aryloxy;

R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl; C_{2-6} alkynyl; cycloalkyl; cycloalkyl-C_{1-6} alkyl; cycloheteroalkyl; cycloheteroalkyl-C_{1-6} alkyl; aryl; heteroaryl; aryl-C_{1-6} alkyl; and heteroaryl-C_{1-6} alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to two substituents independently selected from a R^e;

each R^e is selected from halo, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;

m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, and 4;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.

4. The compound according to Claim 3, wherein:
R^1 is selected from the group consisting of:
(1) hydrogen,
(2) methyl,
(3) ethyl, and
(4) propyl,
optionally substituted with one to three substituents independently selected from R^a;

R^2 is selected from the group consisting of:
(1) hydrogen,
(2) C_{1-6} alkyl,
(3) cycloalkyl-C_{0-6} alkyl,

(4) heterocycloalkyl-C_{0-6} alkyl,

(5) aryl-C_{0-6} alkyl, and

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b;

or, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, optionally containing one additional heteroatom selected from N, S, and O, either unsubstituted or substituted with an R^b substituent;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) C_{1-8} alkyl,

(4) trifluoromethyl,

(5) –OH,

(6) $-OCH_3$,

(7) $-NH_2$,

(8) $-CO_2H$,

(9) $-CO_2CH_3$,

(10) $-CO_2CH_2CH_3$, and

(11) $-C(O)NH_2$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a;

R^4 is selected from the group consisting of:

(1) C_{1-8} alkyl,

(2) trifluoromethyl,

(3) cycloalkyl,

(4) cycloheteroalkyl,

(5) aryl,

(6) heteroaryl,

(7) $-NH_2$,

(8) $-CO_2H$,
(9) CO_2CH_3, and
(10) $-CO_2CH_2CH_3$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent;

or, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a 5- to 7-membered cycloalkyl ring, either unsubstituted or substituted with oxo or hydroxy;

R^5 is selected from:
(1) hydrogen,
(2) halogen,
(3) methyl,
(4) trifluoromethyl,
(5) hydroxy, and
(6) methoxy;

R^6 is selected from the group consisting of :
(1) $-(CH_2)_n-R^7$,
(2) $-(CH_2)_n$-aryl-R^7,
(3) $-(CH_2)_n$-heteroaryl-R^7,
(4) $-(CH_2)_n$-heterocycloalkyl-R^7,
(5) $-(CH_2)_nCON(R^7)_2$,
(6) $-(CH_2)_nNR^7C(O)R^7$,
(7) $-(CH_2)_nNR^7C(O)(CH_2)_nSR^7$
(8) $-(CH_2)_nNR^7C(O)N(R^7)_2$,
(9) $-(CH_2)_nNHSO_2R^7$,
(10) $-(CH_2)_nN(R^7)_2$, and
(11) $-(CH_2)_nNR^7SO_2N(R^7)_2$,

wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a;

R^7 is independently selected at each occurrence from the group consisting of

(1) hydrogen,
(2) C_{1-6} alkyl,
(3) aryl,
(4) heteroaryl,
(5) cycloalkyl,
(6) heterocycloalkyl,
(7) aryl C_{1-3} alkyl,
(8) heteroaryl C_{1-3} alkyl,
(9) cycloalkyl C_{1-3} alkyl,
(10) heterocycloalkyl C_{1-3} alkyl,
(11) aryl C_{2-3} alkenyl,
(12) heteroaryl C_{2-3} alkenyl,
(13) cycloalkyl C_{2-3} alkenyl, and
(14) heterocycloalkyl C_{2-3} alkenyl,

wherein the alkyl and alkenyl moieties are optionally substituted with one to three substituents selected from R^a; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

each R^a is independently selected from:

(1) $-OR^d$,
(2) $-NHSO_2CH_3$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mCH_3$,
(6) $-SR^d$,
(7) $-S(O)_2OR^d$,
(8) $-S(O)_pN(R^d)_2$,
(9) $-N(R^d)_2$,
(10) $-O(CR^dR^d)_nN(R^d)_2$,
(11) $-C(O)R^d$,
(12) $-CO_2R^d$,
(13) $-CO_2(CR^dR^d)_nCON(R^d)_2$,
(14) $-OC(O)R^d$,

(15) -CN,
(16) -C(O)N(R^d)$_2$,
(17) -NR^dC(O)R^d,
(18) -OC(O)N(R^d)$_2$,
(19) -NR^dC(O)OR^d,
(20) -NR^dC(O)N(R^d)$_2$,
(21) -CR^d(N-OR^d),
(22) -CF_3,
(23) cycloalkyl,
(24) cycloheteroalkyl, and
(25) oxo;

each R^b is independently selected from:
(1) R^a,
(2) -Sn(CH_3)$_3$,
(3) C_{1-6} alkyl,
(4) C_{2-6} alkenyl,
(5) heteroaryl,
(6) aryl, and
(7) aryl-C_{1-10} alkyl;
wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R^a and R^b are optionally substituted with one to four substituents selected from a group independently selected from R^c;

each R^c is independently selected from:
(1) halogen,
(2) amino,
(3) carboxy,
(4) C_{1-4} alkyl,
(5) C_{1-4} alkoxy,
(6) aryl,
(7) aryl C_{1-4} alkyl-,
(8) hydroxy,
(9) -CF_3,

(10) -OC(O)C_{1-4} alkyl,
(11) -OC(O)N(R^d)$_2$, and
(12) aryloxy;

R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl; C_{2-6} alkynyl; cycloalkyl; cycloalkyl-C_{1-6} alkyl; cycloheteroalkyl; cycloheteroalkyl-C_{1-6} alkyl; aryl; heteroaryl; aryl-C_{1-6} alkyl; and heteroaryl-C_{1-6} alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to two substituents independently selected from a R^e;
each R^e is selected from halogen, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;

m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, and 4;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.

5. The compound according to Claim 4, wherein:
R^1 is selected from the group consisting of:
(1) hydrogen,
(2) methyl,
(3) ethyl, and
(4) propyl,
optionally substituted with one to three substituents independently selected from R^a;
R^2 is selected from the group consisting of:
(1) hydrogen,
(2) methyl,
(3) ethyl,
(4) n-propyl,
(5) isopropyl,
(6) t-butyl,
(7) n-butyl,
(8) cyclopropyl,

(9) cyclobutyl,
(10) cyclopentyl,
(11) cyclohexyl,
(12) heterocycloalkyl-C_{0-6} alkyl, wherein the heterocycloalkyl moiety is selected from azetidinyl, pyrrolidinyl, and pyridyl, and
(13) phenyl-C_{0-3} alkyl,

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with one to three substituents independently selected from R^b;

or, R^1 and R^2 together with the nitrogen atom to which they are attached, form a 4- to 10-membered bridged or unbridged heterocyclic ring, selected from: azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, 1-thia-4-azacyclohexyl, azacycloheptyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptyl, 7-azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 2-azabicyclo[2.2.2]octyl, and 3-azabicyclo[3.2.2]nonyl, either unsubstituted or substituted with an R^b substituent;

R^3 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C_{1-8} alkyl,
(4) trifluoromethyl,
(5) –OH,
(6) $-OCH_3$,
(7) $-NH_2$,
(8) $-CO_2H$,
(9) $-CO_2CH_3$, and
(10) $-CO_2CH_2CH_3$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a;

R^4 is independently selected from the group consisting of
(1) C_{1-8} alkyl,
(2) trifluoromethyl,

(3) cyclobutyl,
(4) cyclopentyl,
(5) cyclohexyl,,
(6) phenyl,
(7) $-CO_2H$,
(8) $-CO_2CH_3$, and
(9) $-CO_2CH_2CH_3$;

wherein alkyl moieties above are optionally substituted with one to three substituents independently selected from R^a; and wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties above are optionally substituted with an R^b substituent;

or, R^3 and R^4 together with the ring carbon atoms to which they are attached, form a cyclohexyl ring, either unsubstituted or substituted with oxo or hydroxy;

R^5 is hydrogen;

R^6 is selected from the group consisting of :

(1) $-R^7$,
(2) -heteroaryl-R^7,
(3) $-CONHR^7$,
(4) $-CON(R^7)(CH_3)$,
(5) $-CH_2CONHR^7$,
(6) $-CH_2CON(R^7)(CH_3)$,
(7) $-CH_2NHC(O)R^7$,
(8) $-NHC(O)R^7$,
(9) $-(CH_2)_nNHC(O)(CH_2)_nSR^7$
(10) $-(CH_2)_nNHC(O)N(CH_3)(R^7)$,
(11) $-(CH_2)_nNHC(O)NH(R^7)$,
(12) $-(CH_2)_nNHSO_2R^7$,
(13) $-NH(R^7)$,
(14) $-N(COCH_3)(R^7)$,
(15) $-(CH_2)_nNH(R^7)$, and
(16) $-(CH_2)_nN(COCH_3)(R^7)$,

wherein one or two of the hydrogen atoms in $(CH_2)_n$ may be substituted with R^a;

R^7 is independently selected at each occurrence from the group consisting of

(1) hydrogen,

(2) C_{1-6} alkyl,

(3) aryl, selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,

(4) heteroaryl, selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,

(5) cycloalkyl, selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo [2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl,

(6) heterocycloalkyl, selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl,indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl,

(7) aryl C_{1-3} alkyl, wherein the aryl moiety is selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl,

spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,

(8) heteroaryl C_{1-3} alkyl, wherein the heteroaryl moiety is selected: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,

(9) cycloalkyl C_{1-3} alkyl, wherein the cycloalkyl moiety is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo [2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl,

(10) heterocycloalkyl C_{1-3} alkyl, wherein the heterocycloalkyl moiety is selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl,indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl,

(11) aryl C_{2-3} alkenyl, wherein the aryl moiety is selected from: phenyl, naphthyl, indanyl, indenyl, indolyl, quinazolinyl, quinolinyl, benzthiazolyl, benzoxazolyl, dihydroindanyl, benzisodiazolyl, spirocyclohexylindolinyl, spiro-(dihydrobenzothiophenyl)piperidinyl, spiro-indolinylpiperidinyl, indolinyl, tetrahydroisoquinolinyl, isoindolinyl, benzothiadiazolyl, benzotriazolyl, 1,3-dihydro-2-benzofuranyl, benzothiophenyl, benzodioxolyl, tetrahydronaphthyl,

2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, and 1,4-benzodioxanyl,

(12) heteroaryl C_{2-3} alkenyl, wherein the heteroaryl moiety is selected from: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo[2,3-b]pyridyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, benzisodiazolyl, triazolopyrimidinyl, 5,6,7,8-tetrahydroquinolinyl, 2,1,3-benzothiadiazolyl, and thienopyridinyl,

(13) cycloalkyl C_{2-3} alkenyl, wherein the cycloalkyl moiety is selected from: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronaphthyl, decahydronaphthyl, indanyl, bicyclo [2.2.2]octanyl, tetrahydronaphthyl, and dihydroindanyl, and

(14) heterocycloalkyl C_{2-3} alkenyl, wherein the heterocycloalkyl moiety is selected from: azetidinyl, pyridyl, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl, morpholinyl, 1-thia-4-aza-cyclohexane, 2,5-diazabicyclo[2.2.2]octanyl, 2,3-dihydrofuro[2,3-b]pyridyl, benzoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydroindolyl,indolyl, indolinyl, isoindolinyl, 1,3-dihydro-2-benzofuranyl, benzodioxolyl, hexahydrothienopyridinyl, thienopyridinyl, azacycloheptyl, 4,4-spiro[2,3-dihydrobenzothiophen-3,3-yl]piperidinyl, and 4,4-spiro[indoli-3,3-yl]piperidinyl;

wherein the alkyl moieties are optionally substituted with one to three substituents selected from R^a; and wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties are independently substituted with one to three substituents selected from R^b; and wherein sulfur-containing heterocyclic rings may be mono- or di-oxidized on the sulfur atom;

each R^a is independently selected from:

(1) $-OR^d$,

(2) $-NHSO_2CH_3$,

(3) $-NO_2$,

(4) halogen,

(5) $-S(O)_mCH_3$,

(6) –SCH_3,
(7) -SCF_3,
(8) -$S(O)_2OH$,
(9) -$S(O)_pN(R^d)_2$,
(10) -$N(CH_3)_2$,
(11) -NH_2,
(12) -$O(CR^dR^d)_nN(R^d)_2$,
(13) -$C(O)R^d$,
(14) -CO_2H,
(15) -CO_2CH_3,
(16) t-butyloxycarbonyl,
(17) -$CO_2(CR^dR^d)_nCON(R^d)_2$,
(18) -$OC(O)R^d$,
(19) -CN,
(20) -$C(O)N(R^d)_2$,
(21) -$NR^dC(O)R^d$,
(22) -$OC(O)N(R^d)_2$,
(23) -$NR^dC(O)OR^d$,
(24) -$NR^dC(O)N(R^d)_2$,
(25) -$CR^d(N\text{-}OR^d)$,
(26) -CF_3,
(27) cycloalkyl,
(28) cycloheteroalkyl, and
(29) oxo;

each R^b is independently selected from:

(1) -R^a,
(2) -$Sn(CH_3)_3$,
(3) $C_{1\text{-}6}$ alkyl,
(4) $C_{2\text{-}6}$ alkenyl,
(5) heteroaryl,
(6) phenyl, and
(7) phenyl-$C_{1\text{-}10}$ alkyl;

wherein alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl moieties in R^a and R^b are optionally substituted with one to four substituents selected from a group independently selected from R^c;

each R^c is independently selected from:

(1) halogen,
(2) amino,
(3) carboxy,
(4) C_{1-4} alkyl,
(5) C_{1-4} alkoxy,
(6) aryl,
(7) aryl C_{1-4} alkyl,
(8) hydroxy,
(9) $-CF_3$,
(10) $-OC(O)C_{1-4}$ alkyl,
(11) $-OC(O)N(R^d)_2$, and
(12) aryloxy;

R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl; C_{2-6} alkynyl; cycloalkyl; cycloalkyl-C_{1-6} alkyl; cycloheteroalkyl; cycloheteroalkyl-C_{1-6} alkyl; aryl; heteroaryl; aryl-C_{1-6} alkyl; and heteroaryl-C_{1-6} alkyl;
wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, heteroaryl, and aryl in R^d are optionally substituted with one to two substituents independently selected from a R^e;
each R^e is selected from halogen, methyl, methoxy, trifluoromethyl, trifluoromethoxy, and hydroxy;

m is selected from 1 and 2;
n is selected from: 0, 1, 2, 3, and 4;
p is selected from 0, 1, and 2;
and pharmaceutically acceptable salts thereof.

6. A compound according to Claim 1, of structural formula:



wherein R^4 and R^7 are selected according to the table below:

Ex. #	R^7	R^4
1		-n-propyl
2		-n-propyl
3		-n-propyl
4		-n-propyl
5		-n-propyl
6		-n-propyl
7		-n-propyl
8		-n-propyl
9		-n-propyl
10		-n-propyl
11		-n-propyl
12		-n-propyl

13		-n-propyl
14		-n-propyl
15		-n-propyl
16		-n-propyl
17		-n-propyl
18		-n-propyl
19		-n-propyl
20		-n-propyl
21		-n-propyl
22		-n-propyl
23		-n-propyl
24		-n-propyl
25		-n-propyl
26		-n-propyl
27		-n-propyl

28		-n-propyl
29		-n-propyl
30		-n-propyl
31		-n-propyl
32		-n-propyl
33		-n-propyl
34		-n-propyl
35		-n-propyl
36		-n-propyl
37		-n-propyl
38		-n-propyl
39		-n-propyl
40		-n-propyl
41		-n-propyl
42		-n-propyl

43		-n-propyl
44		-n-propyl
45		-n-propyl
46		-n-propyl
47		-n-propyl
48		-n-propyl
49		-n-propyl
50		-n-propyl
51		-n-propyl
52		-n-propyl
53		-n-propyl
54		-n-propyl
55		-n-propyl
56		-n-propyl
57		-n-propyl

58		-n-propyl
59		-n-propyl
60		-n-propyl
61		-n-propyl
62		-n-propyl
63		-n-propyl
64	 isomer A	-n-propyl
65	 isomer B	-n-propyl
66		-n-propyl
67		-n-propyl
68		-n-propyl
69		-n-propyl
70		-n-propyl
71		-n-propyl

72		-n-propyl
73		-n-propyl
74		-n-propyl
75		-n-propyl
76		-n-propyl
77		-n-propyl
78		-n-propyl
79		
80		
81		
82		

83		
84		
85		
86		
87		
88		
89		
90		
91		
92		
93		
94		
95		
96		
97		
98		

99		
100		
101		
102		
103		
104		
105		
106		
107		
108		
109		
110		
111		
112		
113		

114	 (isomer A)	
115	 (isomer B)	
116		
117		
118		
119		
120		
121		
122		
123		
124		
125		
126		
127		

and pharmaceutically acceptable salts thereof.

7. A compound according to Claim 1, of structural formula:



wherein -R^7 and -R are selected according to the table below:

Ex.#	R^7	$R = -NR^1R^2$
128		
129		
130		
131		
132		
133		
134	 isomer A	
135	 isomer A	

136		
137		
138		
139		
140		
141		
142		

143		
144		
145		
146		
147		
148		
149		
150		
151		
152		
153		
154		
155		

and pharmaceutically acceptable salts thereof.

8. The compound according to Claim 1 which is selected from the following:

Ex.#	Structure

156	
157	
158	
159	
160	
161	
162	
163	
164	

165	
166	

and pharmaceutically acceptable salts thereof.

9. The compound according to Claim 1, of structural formula:



wherein R^6 and R^4 are selected according to the table below:

Ex. #	R^6	R^4
167		
168		
169		
170		

171		
172		
173		
174		
175		
176		
177		
178		
179		
180		

181		
182		
183		
184		
185		
186		
187		
188		
189		

190		
191		
192		
193		
194A		
194B		
195		
196		
197		

198		
199		
200		
201		
202		
203		
204		
205		
206		

207		
208		
209		
210		
211		
212		
213		
214		
215		
216		
217		

218		
219		
220		
221		
222		
223		
224		
225		
226		
227		
228		
229		

230		
231		
232		
233		
234		
235		
236		
237		
238		
239		

240		
241		
242		
243		
244		

10. The compound according to Claim 1, selected from the group consisting of:

(1) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(2) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(2,4-dichlorophenyl)prop-2-enamide,

(3) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(1,1'-biphenyl-4-yl)prop-2-enamide,

(4) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-bromophenyl)prop-2-enamide,

(5) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(6) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-methylphenyl)prop-2-enamide,

(7) *N*-(4-amino-2-propylquinolin-6-yl)-1,1'-biphenyl-4-carboxamide,

(8) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-[4-(methylthio)phenyl]prop-2-enamide,

(9) (2*E*)-*N*-[4-(dimethylamino)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(10) *N*-(4-amino-2-propylquinolin-6-yl)-4'-(trifluoromethyl)-1,1'-biphenyl-4-carboxamide,

(11) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-iodophenyl)prop-2-enamide,
(12) (2*E*)-*N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(13) (2*E*)-*N*-[4-(methylamino)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(14) (2*E*)-*N*-(4-amino-2-ethylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(15) (2*E*)-*N*-(4-amino-2-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(16) (2*E*)-*N*-(4-amino-2-ethylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,
(17) (2*E*)-*N*-(4-amino-2-butylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,
(18) *N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,
(19) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-ethylphenyl)prop-2-enamide,
(20) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-isopropylphenyl)prop-2-enamide,
(21) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-propylphenyl)prop-2-enamide,
(22) *N*-[4-amino-3-(hydroxymethyl)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]propanamide,
(23) (2*E*)-*N*-[4-amino-2-(methoxymethyl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(24) (2*E*)-*N*-(4-amino-2-hexylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(25) (2*E*)-*N*-[4-amino-2-(methoxymethyl)quinolin-6-yl]-3-(4-chlorophenyl)prop-2-enamide,
(26) (2*E*)-*N*-(4-amino-2-pentylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,
(27) (2*E*)-*N*-(4-amino-2-pentylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,
(28) (2*E*)-*N*-(4-amino-2-hexylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,
(29) *N*-(4-amino-2-propylquinolin-6-yl)-4-(4-chlorophenyl)cyclohexanecarboxamide,
(30) *N*-(4-amino-2-propylquinolin-6-yl)-4'-chloro-1,1'-biphenyl-4-carboxamide,
(31) *N*-[4-(methylamino)-2-propylquinolin-6-yl]-4'-(trifluoromethyl)-1,1'-biphenyl-4-carboxamide,
(32) *N*-(4-amino-2-propylquinolin-6-yl)-4'-ethyl-1,1'-biphenyl-4-carboxamide,

(33) (2*E*)-*N*-(4-amino-2-isopropylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(34) (2*E*)-*N*-(4-amino-2-isopropylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(35) *N*-(4-amino-2-isopropylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,

(36) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-[6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide,

(37) (2*E*)-*N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(38) *N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-4'-chloro-1,1'-biphenyl-4-carboxamide,

(39) (2*E*)-*N*-(9-amino-8-oxo-5,6,7,8-tetrahydroacridin-2-yl)-3-(4-chlorophenyl)prop-2-enamide,

(40) (2*E*)-*N*-[4-amino-2-(hydroxymethyl)quinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(41) (2*E*)-*N*-(9-amino-5,6,7,8-tetrahydroacridin-2-yl)-3-(4-chlorophenyl)prop-2-enamide,

(42) (2*E*)-*N*-(9-amino-8-hydroxy-5,6,7,8-tetrahydroacridin-2-yl)-3-(4-chlorophenyl)prop-2-enamide,

(43) (2*E*)-*N*-(9-amino-5,6,7,8-tetrahydroacridin-2-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(44) (2*E*)-*N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(45) (2*E*)-*N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(46) (2*E*)-3-(4-chlorophenyl)-*N*-[4-(ethylamino)-2-propylquinolin-6-yl]prop-2-enamide,

(47) (2*E*)-*N*-[4-(ethylamino)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(48) (2*E*)-*N*-(4-amino-2-*tert*-butylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(49) (2*E*)-*N*-(4-amino-2-*tert*-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(50) *N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,

(51) (2*E*)-*N*-(4-amino-2-neopentylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(52) *N*-(4-amino-2-isopropylquinolin-6-yl)-*N'*-(4-phenoxyphenyl)urea

(53) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-ethylcyclohexyl)prop-2-enamide,

(54) (2*E*)-*N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-(4-iodophenyl)prop-2-enamide,

(55) *N*-(4-amino-2-isopropylquinolin-6-yl)-*N'*-(4-phenylcyclohexyl)urea,

(56) *N*-(4-amino-2-isopropylquinolin-6-yl)-*N'*-(2-naphthyl)urea,

(57) (2*E*)-*N*-(4-amino-2-cyclobutylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(58) (2*E*)-*N*-(4-amino-2-cyclopentylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(59) (2*E*)-*N*-(4-amino-2-cyclohexylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(60) (2*E*)-*N*-(4-amino-2-cyclobutylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(61) (2*E*)-*N*-(4-amino-2-cyclopentylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(62) (2*E*)-*N*-(4-amino-2-cyclohexylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(63) (2*E*)-*N*-(4-amino-2-methylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(64) 2-propyl-6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-4-amine,

and pharmaceutically acceptable salts thereof.

11. The compound according to Claim 10 selected from:

(1) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(2) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(3) (2*E*)-*N*-[4-(dimethylamino)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(4) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-iodophenyl)prop-2-enamide,

(5) (2*E*)-*N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(6) (2*E*)-*N*-[4-(methylamino)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(7) *N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,

(8) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-ethylphenyl)prop-2-enamide,

(9) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-(4-isopropylphenyl)prop-2-enamide,

(10) *N*-(4-amino-2-propylquinolin-6-yl)-4'-chloro-1,1'-biphenyl-4-carboxamide,

(11) *N*-[4-(methylamino)-2-propylquinolin-6-yl]-4'-(trifluoromethyl)-1,1'-biphenyl-4-carboxamide,

(12) (2*E*)-*N*-(4-amino-2-isopropylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(13) (2*E*)-*N*-(4-amino-2-isopropylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(14) *N*-(4-amino-2-isopropylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,

(15) (2*E*)-*N*-(4-amino-2-propylquinolin-6-yl)-3-[6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide,

(16) (2*E*)-*N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(17) *N*-(4-azetidin-1-yl-2-propylquinolin-6-yl)-4'-chloro-1,1'-biphenyl-4-carboxamide,

(18) (2*E*)-*N*-(9-amino-8-oxo-5,6,7,8-tetrahydroacridin-2-yl)-3-(4-chlorophenyl)prop-2-enamide,

(19) (2*E*)-*N*-(9-amino-5,6,7,8-tetrahydroacridin-2-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(20) (2*E*)-*N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(21) (2*E*)-*N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(22) (2*E*)-3-(4-chlorophenyl)-*N*-[4-(ethylamino)-2-propylquinolin-6-yl]prop-2-enamide,

(23) (2*E*)-*N*-[4-(ethylamino)-2-propylquinolin-6-yl]-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(24) (2*E*)-*N*-(4-amino-2-*tert*-butylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(25) (2*E*)-*N*-(4-amino-2-*tert*-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(26) *N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]propanamide,

(27) *N*-(4-amino-2-isopropylquinolin-6-yl)-*N'*-(4-phenoxyphenyl)urea

(28) (2*E*)-*N*-(4-amino-2-*sec*-butylquinolin-6-yl)-3-(4-iodophenyl)prop-2-enamide,

(29) (2*E*)-*N*-(4-amino-2-cyclobutylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(30) (2*E*)-*N*-(4-amino-2-cyclopentylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(31) (2*E*)-*N*-(4-amino-2-cyclohexylquinolin-6-yl)-3-(4-chlorophenyl)prop-2-enamide,

(32) (2*E*)-*N*-(4-amino-2-cyclobutylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(33) (2*E*)-*N*-(4-amino-2-cyclopentylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(34) (2*E*)-*N*-(4-amino-2-cyclohexylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(35) (2*E*)-*N*-(4-amino-2-methylquinolin-6-yl)-3-[4-(trifluoromethyl)phenyl]prop-2-enamide,

(36) 2-propyl-6-(5-{2-[4-(trifluoromethyl)phenyl]ethyl}-1,2,4-oxadiazol-3-yl)quinolin-4-amine,

and pharmaceutically acceptable salts thereof.

12. A method of treating or suppressing a disease mediated by the MCH receptor in a subject in need thereof comprising administeration of a therapeutically effective amount of a compound according to Claim 1.

13. The method according to Claim 12 wherein the disease is mediated by the MCH1R receptor.

14. The method according to Claim 12 wherein the disease mediated by the MCH receptor is selected from: obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, gall stones, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), binge eating disorders including bulimina, anorexia, mental disorders including manic depression, depression, schizophrenia, mood disorders, delirium, dementia, severe mental retardation, anxiety, stress, cognitive disorders, sexual function, reproductive function, kidney function, diuresis, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias including Parkinson's disease, Parkinson-like syndromes, Tourette's syndrome, Huntington's disease, epilepsy, improving memory function, and spinal muscular atrophy.

15. A method of treating obesity in a subject in need thereof comprising administration of a therapeutically effective amount of a compound according to Claim 1.

16. The method according to Claim 15, additionally comprising administration of a therapeutically effective amount of an anorectic agent or a selective serotonin reuptake inhibitor.

17. The method according to Claim 16 wherein: the anorectic agent is selected from: aminorex, amphechloral, amphetamine, benzphetamine, chlorphentermine, clobenzorex, cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine, dextroamphetamine, diethylpropion, diphemethoxidine, *N*-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex, fenproporex, fludorex, fluminorex, furfurylmethylamphetamine, levamfetamine, levophacetoperane, mazindol, mefenorex, metamfepramone, methamphetamine, norpseudoephedrine, pentorex, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picilorex and sibutramine; and the selective serotonin reuptake inhibitor is selected from: fluoxetine, fluvoxamine, paroxetine and sertraline.

18. A method of preventing obesity in a person at risk for obesity comprising administration to said person of about 0.01 mg to about 100 mg per kg of a compound according to Claim 1.

19. A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

20. The use of a compound of Claim 1 for the manufacture of a medicament useful for the treatment or prevention, or suppression of a disease mediated by the MCH-1R receptor in a human subject in need thereof.

21. The use of a compound of Claim 1 for the manufacture of a medicament useful for the treatment, prevention or suppression of obesity in a human subject in need thereof.

22. A method of treating a condition selected from schizophrenia, bipolar disorder and depression in a subject in need thereof comprising administering an effective amount of an MCH-1R receptor antagonist compound to the subject.

23. A method of treating depression in a subject in need thereof comprising administering an effective amount of an MCH-1R receptor antagonist compound according to Claim 1 to the subject.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/37510

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 215/42
US CL :546/162

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/162

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LANZA T.J. et al., Substituted 4,6-Diaminoquinolines as Inhibitors of C5a Receptor Binding, J. Med. Chem., 1992. Vol. 35, No. 2, pages 252-258, especially page 254.	11

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 05 FEBRUARY 2003	Date of mailing of the international search report 28 FEB 2003
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Patricia L. Morris Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet) (July 1998)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/37510

BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE

2. Where no meaningful search could be carried out, specifically:

In these claims, the numerous variables and their voluminous, complex meanings and their seemingly endless permutations and combinations, make it virtually impossible to determine the full scope and complete meaning of the claimed subject matter. As presented, the claimed subject matter cannot be regarded as being a clear and concise description for which protection is sought and such the listed claims do not comply with the requirements of PCT Article 6. Thus, it is impossible to carry out a meaningful search on same. A search will me made on the first discernible invention of claim 11, the first compound recited.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/37510

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-10 and 12-23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.